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Preamble
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) support their
members’ goal to improve the prevention and care of
cardiovascular diseases through professional education, re-
search, and development of guidelines and standards and by
fostering policy that supports optimal patient outcomes.
The ACCF and AHA recognize the importance of the use
of clinical data standards for patient management, assess-
ment of outcomes, and conduct of research, and the
importance of defining the processes and outcomes of
clinical care, whether in randomized trials, observational
studies, registries, or quality-improvement initiatives.
Hence, clinical data standards strive to define and stan-
dardize data relevant to clinical topics in cardiology, with
the primary goal of assisting data collection by providing a
utcomes of patients with acute coronary syndromes and coronary artery disease: a
eport of the American College of Cardiology Foundation/American Heart Associ-
tion Task Force on Clinical Data Standards (Writing Committee to Develop Acute
oronary Syndromes and Coronary Artery Disease Clinical Data Standards). J Am
oll Cardiol 2013;61:xxx–xxx, doi:10.1016/j.jacc.2012.10.005.
This article is copublished in Circulation and Critical Pathways in Cardiology.
Copies: This document is available on the World Wide Web sites of the
merican College of Cardiology (http://www.cardiosource.org) and the American
eart Association (my.americanheart.org). For copies of this document, please
ontact Elsevier Inc. Reprint Department, fax 212-633-3820, e-mail reprints@
lsevier.com.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribu-
ion of this document are not permitted without the express permission of the American
ollege of Cardiology Foundation. Please contact healthpermissions@elsevier.com.
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various conditions. Broad agreement on a common vocab-
ulary with reliable definitions used by all is vital to pool
and/or compare data across studies to promote interopera-
bility of electronic health records (EHRs) and to assess the
applicability of research to clinical practice. The increasing
national focus on adoption of certified EHRs along with
financial incentives for providers to demonstrate “meaning-
ful use” of those EHRs to improve healthcare quality render
even more imperative and urgent the need for such defini-
tions and standards. Therefore, the ACCF and AHA have
undertaken to define and disseminate clinical data stan-
dards—sets of standardized data elements and correspond-
ing definitions—to collect data relevant to cardiovascular
conditions. The ultimate purpose of clinical data standards
is to contribute to the infrastructure necessary to accomplish
the ACCF/AHA mission of fostering optimal cardiovascu-
lar care and disease prevention and building healthier lives,
free of cardiovascular diseases and stroke.
The specific goals of clinical data standards are
1. To establish a consistent, interoperable, and universal
clinical vocabulary as a foundation for both clinical care
and clinical research
2. To promote the ubiquitous use of EHRs and facilitate
the exchange of data across systems through harmo-
nized, standardized definitions of key data elements
3. To facilitate the further development of clinical regis-
tries, quality- and performance-improvement pro-
grams, outcomes evaluations, and clinical research,
including the comparison of results within and across
these initiatives
The key elements and definitions are a compilation of
variables intended to facilitate the consistent, accurate, and
reproducible capture of clinical concepts; standardize the
terminology used to describe cardiovascular diseases and
procedures; create a data environment conducive to the
assessment of patient management and outcomes for quality
and performance improvement and clinical and translational
research; and increase opportunities for sharing data across
disparate data sources. The ACCF/AHA Task Force on
Clinical Data Standards selects cardiovascular conditions
and procedures that will benefit from creation of a data
standard set. Experts in the subject are selected to examine/
consider existing standards and develop a comprehensive,
yet not exhaustive, data standard set. When undertaking a
data collection effort, only a subset of the elements con-
tained in a clinical data standards listing may be needed, or
conversely, users may want to consider whether it may be
necessary to collect some elements not listed. For example,
in the setting of a randomized clinical trial of a new drug,
additional information would likely be required regarding
study procedures and drug therapies.
The ACCF and AHA recognize that there are other
national efforts to establish clinical data standards, and every
attempt is made to harmonize newly published standardswith existing standards. Writing committees are instructed
to consider adopting or adapting existing nationally recog-
nized data standards if the definitions and characteristics are
useful and applicable to the set under development. In
addition, the ACCF and AHA are committed to continu-
ally expanding their portfolio of data standards and will
create new standards and update existing standards as
needed to maintain their currency and promote harmoniza-
tion with other standards as health information technology
and clinical practice evolve.
The Health Insurance Portability and Accountability Act
privacy regulations, which went into effect in April 2003,
have heightened all practitioners’ awareness of our profes-
sional commitment to safeguard our patients’ privacy. The
Health Insurance Portability and Accountability Act privacy
regulations (1) specify which information elements are consid-
ered “protected health information.” These elements may not
be disclosed to third parties (including registries and research
studies) without the patient’s written permission. Protected
health information may be included in databases used for
healthcare operations under a data use agreement. Research
studies using protected health information must be reviewed by
an institutional review board or a privacy board.
We have included identifying information in all clinical data
standards to facilitate uniform collection of these elements
when appropriate. For example, a longitudinal clinic database
may contain these elements because access is restricted to the
patient’s caregivers. Conversely, registries may not contain
protected health information unless specific permission is
granted by each patient. These fields are indicated as protected
health information in the data standards.
The ACCF/AHA Task Force on Clinical Data Stan-
dards makes every effort to avoid any actual or potential
conflicts of interest that may arise as a result of an outside
relationship or a personal, professional, or business interest
of a member of the writing panel. Specifically, all members
of the writing committee were required to submit a disclo-
sure form showing all such relationships that might be
perceived as real or potential conflicts of interest. These
statements were reviewed by the ACCF/AHA Task Force
on Clinical Data Standards, reported orally to all members
of the writing panel at the first meeting, and updated as
changes occur.
In clinical care, caregivers communicate with each other
through a common vocabulary. In an analogous fashion, the
integrity of clinical research depends on firm adherence to
prespecified procedures for patient enrollment and follow-
up; these procedures are guaranteed through careful atten-
tion to definitions enumerated in the study design and case
report forms. When data elements and definitions are
standardized across studies, comparison, pooled analysis,
and meta-analysis are enabled, thus deepening our under-
standing of individual studies.
The recent development of quality-performance mea-
surement initiatives, particularly those for which the com-
parison of providers is an implicit or explicit aim, has further
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Indeed, a wide audience, including nonmedical profession-
als such as payers, regulators, and consumers, may draw
conclusions about care and outcomes. To understand and
compare care patterns and outcomes, the data elements that
characterize them must be clearly defined, consistently used,
and properly interpreted, now more than ever before.
Robert C. Hendel, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Clinical Data Standards
1. Introduction
In the field of cardiology, large-scale clinical trials and
registries have provided a wealth of data on the treatment
and outcomes for hundreds of thousands of patients. Many
of these efforts have focused on patients with acute coronary
syndromes (ACS), which range from ST-segment elevation
myocardial infarction (STEMI) to non–ST-segment eleva-
tion myocardial infarction (NSTEMI) to unstable angina
(UA). These data have been used to evaluate the effective-
ness of the pharmacological and interventional management
of these patients, define new therapies, and guide clinical
care through evaluation of both the process and the quality
of care and outcomes for patients with ACS.
The ACCF and AHA, in conjunction with other pro-
fessional medical organizations and government agencies,
recognize the importance of using clinical data and, to that
end, have aimed to establish a series of datasets in the major
areas of cardiology (2–7). In 2001, a dataset was established
for the field of ACS; a working group developed a list of key
data elements to characterize patients with ACS. This
document served as the basis for data definitions for many
data elements in the ACTION Registry–Get With The
Guidelines (AR-G), Get With The Guidelines–CAD
(GWTG-CAD), and other trials and registries. To date,
this document has been cited in 255 publications.
Given the overlap of ACS and coronary artery disease
(CAD), it was decided to update this list of data elements
and expand it to include CAD. The current group of
organizations also has been expanded to include as many
organizations with an interest in clinical data standards for
ACS/CAD as could be identified. In addition, the cardiac
catheterization/percutaneous coronary intervention (Cath/
PCI) registry of the National Cardiovascular Data Reg-
istry also includes patients with ACS and CAD, and as
such the elements overlap as well. Thus, the goal was to
create definitions that could serve registries in all these
areas and in particular those that matched between
AR-G and Cath/PCI.
The writing committee hopes that this set of data
elements and definitions for patients with ACS and CAD
will help facilitate research and assessment of quality of care,
thereby advancing the practice of medicine.2. Methodology
2.1. Writing Committee Composition
The process undertaken in developing these clinical data
standards began with the ACCF/AHA Task Force on
Clinical Data Standards, which identified ACS as an
important area in which to standardize definitions and
registries. A writing committee was formed that included a
select group of physicians who have been involved in
large-scale ACS clinical trials or registries and who are
recognized experts in the field. The committee also included
members who are considered to be experts in the diagnosis
and treatment of stable CAD. Additionally, the writing
committee includes several international members to
ensure balance in the data elements and the type of
practice worldwide that would be reflected by the data
collected in this dataset. The writing committee also
included representatives from the American College of
Chest Physicians, American College of Emergency Phy-
sicians, American College of Physicians, American Col-
lege of Preventive Medicine, American Medical Associa-
tion, Emergency Nurses Association, National Association of
Emergency Medical Technicians, National Association of
EMS Physicians, Preventive Cardiovascular Nurses As-
sociation, Society for Academic Emergency Medicine,
Society for Cardiovascular Angiography and Interven-
tions, Society of Cardiovascular Patient Care, Society of
General Internal Medicine, and Society of Thoracic
Surgeons.
2.2. Relationships With Industry and Other Entities
Disclosure of all relationships with industry and other
entities (RWI) is required of every member of ACCF/AHA
data standards writing committees and peer reviewers. This
writing effort was initiated before the implementation of the
updated ACCF and AHA policy on relationships with
industry and other entities, which requires that a majority of
the writing committee plus the writing committee chair
have no relationships with industry and other entities
relevant to the document. Relevant relationships disclosed
by writing committee members and peer reviewers are listed
in Appendixes 1 and 2, respectively. The work of the
riting committee was supported exclusively by the ACCF
nd AHA (and the other partnering organizations) without
ommercial support. Writing committee members volun-
eered their time for this effort. Meetings of the writing
ommittee were confidential and attended only by commit-
ee members and staff.
2.3. Review of Literature and
Existing Data Definitions
Writing committee members compiled and reviewed case
report forms, data elements, and data definitions from
national and international ACS registries and previous or
ongoing clinical trials to develop an initial set of data
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first round are the NRMI (National Registry of Myocardial
Infarction) (8), GRACE (Global Registry of Acute Coro-
nary Events) (9), TIMI (Thrombolysis in Myocardial In-
farction) (10–12), and the GUSTO (Global Use of Strep-
tokinase and Tissue Plasminogen Activator to Open
Occluded Arteries) (13–15) trials, and in this update, the
definitions for the Cath/PCI and AR-G, CRUSADE (Can
Rapid risk stratification of Unstable angina patients Sup-
press Adverse outcomes with Early implementation of the
ACC/AHA Guidelines) (16), and ACTION Registry-
GWTG (17) were reviewed in detail.
This document also considered data elements and how
they pertain to the emergency department (16), the prehos-
pital setting, and Mission: Lifeline (18).
2.4. Defining Data Elements
The data elements reflect an ongoing review of the medical
literature to focus on new developments. Current scientific
evidence provided the basis for the selection and definition
of appropriate data elements required to evaluate and
manage patients with ACS and stable CAD. Therefore,
data elements and definitions were linked whenever possible
to evidence-based national guidelines. For the purposes of
these clinical data standards, the writing committee chose to
review and cite several ACCF/AHA guidelines, including
but not limited to the “ACCF/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial
Infarction” (19,20) and the “ACCF/AHA Guidelines for
the Management of Patients With Unstable Angina/Non–
ST-Elevation Myocardial Infarction” (21). Data element
definitions particularly in the Outcomes section were also
matched to the upcoming Food and Drug Administration
(FDA) definitions for major cardiovascular endpoints. In
addition, the writing committee adopted the definition of
myocardial infarction (MI) as published in a European
Society of Cardiology/ACCF/AHA/World Heart Fed-
eration consensus document on the universal definition of
MI (22). On a few occasions, data elements and defini-
tions were linked to other national guidelines, such as the
National Cholesterol Education Program (NCEP III)
guidelines (23).
The writing committee members reviewed the list of data
elements, bearing in mind the intent of their use. For
example, some data elements are suitable for use in devel-
oping and implementing risk adjustment models, whereas
others can be used to construct performance measures.
Several data elements can be used for multiple purposes.
Additional uses of the data include identification of patient
demographics for combining data across registries and
disease states, institutional and regional variances that may
be addressed in health services research, patient follow-up
for evaluation of long-term effects of therapy, and outcomes
analysis.2.5. Relation to Other Standards
The writing committee reviewed other standards, including
those developed for heart failure, atrial fibrillation, electro-
physiology, and cardiac imaging. It was thought that this
writing committee possessed key levels of expertise needed
to address issues related to ACS and CAD in a consistent
fashion.
2.6. Consensus Development
The writing committee met several times in person and by
conference call to refine the data standards to their present
form. The overriding goals were to focus on important
variables needed to assess patients’ characteristics, their
treatment with both medication and interventional thera-
pies, and their outcomes. In developing the list of data
elements, the writing committee worked to balance the
completeness of the dataset in describing ACS with the
length of the data element set. The goal was to be as
concise as possible to facilitate the use of these variables
in real-world registry or trial settings. Standardized
definitions for each variable are provided. In assembling
these, the writing committee again balanced the in-
creased complexity of obtaining more specific and de-
tailed data required to satisfy more comprehensive defi-
nitions against information that can be readily and
reliably obtained from medical records to make these
definitions more functional and applicable in the various
real-world settings in which they may be used.
2.7. Peer Review, Public Review, and
Board Approval
The “2013 ACCF/AHA Key Elements and Data Defini-
tions for Measuring the Clinical Management and Out-
comes of Patients With Acute Coronary Syndromes and
Coronary Artery Disease” was reviewed by official reviewers
nominated by the ACCF and AHA, as well as official
reviewers designated by collaborating societies. To increase
its applicability further, the document was posted on the
ACC World Wide Web site for a 30-day public comment
period. This document was approved for publication by the
ACCF Board of Trustees on October 19, 2012, and AHA
Science Advisory and Coordinating Committee on Novem-
ber 30, 2012, and was formally endorsed by the American
College of Emergency Physicians, Emergency Nurses As-
sociation, National Association of Emergency Medical
Technicians, National Association of EMS Physicians,
Preventive Cardiovascular Nurses Association, Society for
Cardiovascular Angiography and Interventions, Society of
Cardiovascular Patient Care, and Society of Thoracic Sur-
geons. The writing committee anticipates that these data
standards will require review and updating, just as with
other published guidelines, performance measures, and
appropriateness criteria. The writing committee will review
the set of data elements on a periodic basis, starting with the
anniversary of publication of the standards, to ascertain
whether modifications should be considered.
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Element Name Element Definition
Demographics
Unique patient ID Patient ID is a unique number that permanently identifies each patient. Once assigned to a patient, this number can never be changed or
reassigned to a different patient. Each time a patient returns to the site, the patient MUST receive the same unique patient identifier.
Sex Indicate the patient’s sex at birth as either male or female. Choose 1 of the following:
● Male
● Female
ate of birth Indicate the patient’s date of birth.
ace Indicate the patient’s race as determined by the patient or family. Choose 1 of the following:
● White
● Black or African American
● Asian Indian
● Chinese
● Filipino
● Japanese
● Korean
● Vietnamese
● Other Asian
● American Indian or Alaska Native
● Native Hawaiian
● Guamanian or Chamorro
● Samoan
● Other Pacific Islander
thnicity Indicate if the patient is of Hispanic or Latino ethnicity as determined by the patient or family. Hispanic ethnicity includes patient reports
of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. Choose 1 of the
following:
● No
● Yes
ostal code Indicate the postal code for the patient’s residence. For US ZIP codes, the hyphen is implied. If the patient is determined to not have a
permanent residence, then the patient is considered homeless.
Admission/encounter
date
Indicate the date the patient was admitted as an inpatient to the facility for the current episode of care.
For outpatients, note the date (month/day/year) of the encounter (e.g., physician visit, nurse visit, consultation, procedures).
Admission source Indicate the source of the patient’s admission as an inpatient to your facility.
Choose 1 of the following:
● Physician referral: The patient was admitted to this facility on the recommendation of his or her personal physician.
● Clinic referral: The patient was admitted to this facility on the recommendation of this facility’s clinic physician.
● HMO referral: The patient was admitted to this facility on the recommendation of an HMO physician.
● Transfer from a hospital (different facility): The patient was admitted to this facility as a hospital transfer from a different acute care
facility where he or she was an inpatient.
● Transfer from SNF: The patient was admitted to this facility as a transfer from an SNF where he or she was an inpatient.
● Transfer from another healthcare facility: The patient was admitted to this facility as a transfer from a healthcare facility other than an
acute care facility or an SNF. This includes transfers from nursing homes and long-term care facilities and SNF patients who are at
a nonskilled level of care.
● ED: The patient was admitted to this facility on the recommendation of this facility’s emergency physician.
● Court/law enforcement: The patient was admitted to this facility on the direction of a court of law or the request of a law enforcement
agency representative.
● Information not available: The means by which the patient was admitted to this hospital is not known.
- Transfer from a critical access hospital: The patient was admitted to this facility as a transfer from a critical access hospital where he
or she was an inpatient.
- Transfer from hospital inpatient in the same facility resulting in a separate claim to the payer: The patient was admitted to this
facility as a transfer from hospital inpatient within this facility resulting in a separate claim to the payer.
Insurance payer Indicate the patient’s primary insurance payer for this admission. Choose 1 of the following:
● Government: Refers to patients who are covered by government-reimbursed care. In the United States this includes
- Medicare
- Medicaid (including all state or federal Medicaid-type programs)
- Veterans Health Administration
- Department of Defense
- Other federal group (specify)
● Commercial: Refers to all indemnity (fee-for-service) carriers and PPOs
● HMO: Refers to a HMO characterized by coverage that provides healthcare services for members on a prepaid basis
● None: Refers to patients with limited or no health insurance; thus, the patient is the payer regardless of ability to pay. Only mark
“None” when “self” or “none” is denoted as the first insurance in the medical record.
resentation (to
healthcare facility)
date/time
Date and time the patient first presented to the hospital
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CAD Data Standards
There are many goals that this project hopes to fulfill by
providing a list of key data elements and standardized
definitions in ACS and CAD (Table 1). First, it is hoped
that standardized definitions will facilitate better cross-
comparison of results and clinical outcomes between
different clinical trials and registries. This is particularly
true for meta-analyses of clinical trials, where differences
in data collection methods and variations in definitions
have hampered the validity of these analyses. Further-
more, the standardized definitions would also facilitate
Table 1. Continued
Element Name
Location of first
evaluation in ED
Indicate if the patient was first evaluated in your fac
clinics, and short-stay CCUs housed in the ED.
Transfer out of ED
date/time
If the patient was first evaluated in your facility’s ED
location within your facility or to another acute
Type of admission The categories of type of admission are
● Elective (i.e., scheduled 24 h before hospital arriv
● Urgent (i.e., through the ED or directly from a healt
dmission location The categories of location of a patient at the time of
● CCU/ICU
● Step-down unit/monitored bed/cardiac ward
● Unmonitored hospital floor
● Observation unit/ED chest pain unit
eans of transport of
nontransfer patient
Indicate the means by which a nontransfer patient w
● Self/family
● Ground-transport ambulance (includes 911 provide
● Air ambulance (helicopter or fixed wing)
● Mobile ICU
● Unknown
rearrival first
medical contact
date/time
Indicate the date and time of prearrival first medica
professional before arrival at your facility. This
Note: Enter the date and time of first medical cont
mobile ICU.
Transfer patient Indicate if the patient was transferred directly to you
Means of transport of
transfer patient
Indicate the means by which the transfer patient wa
Choose 1 of the following:
● Mobile ICU
● Air ambulance (helicopter or fixed wing) transfer fr
● Ground-transport ambulance transfer from another
- 911 Provider
- Hospital based
- Private provider
- Unknown
rrival at outside
hospital date/time
Indicate the date and time the patient arrived at the
ransfer from outside
hospital date/time
Indicate the date and time the patient left the outsid
ime points for STEMI
patients
Indicate the following time points for STEMI patients
● Symptom-onset date/time
● EMS dispatch date/time
- If ground or air ambulance, indicate EMS first me
● Non-EMS first medical contact date/time
● EMS leaving scene date/time
● Hospital arrival date/time
● First ECG date/time
● Catheterization lab activation date/time
CCU indicates coronary care unit; ECG, electrocardiogram; ED, emergency department; EMS,
identification; PPO, preferred provider organization; SNF, skilled nursing facility; and STEMI, ST-the application of research findings that come from theclinical trials and registries, because the key elements
needed for assessment of efficacy, safety, and appropriate
risk adjustment would be included in the clinical data
standards.
Second, the provision of a list of the major variables,
outcomes, and definitions should facilitate the development
and implementation of future registries at both individual
hospital and national levels. The standardized definitions
should also standardize and enhance the reporting of re-
search findings coming from the clinical trials and registries,
because the key elements needed for assessment of efficacy
and safety and for appropriate risk adjustment would be
Element Definition
ED. This includes traditional ED locations, as well as ED-based chest pain units,
r the date and time the patient was moved out of the ED, either to another
enter.
provider’s office or transferred from another facility)
ssion to the hospital or observation unit are
nsported to your facility. Choose 1 of the following:
ate provider, or hospital based)
ct, when the patient was first evaluated by either EMS or another healthcare
the date and time of arrival at your facility.
ly for patients who were transported by ambulance (ground or air) or
ity from another ED or hospital unit and indicate which.
sported to your facility.
other facility
care facility
e hospital. If unknown, leave blank.
lity.
contact date/time
ency medical services; HMO, health maintenance organization; ICU, intensive care unit; ID,
t elevation myocardial infarction.ility’s
, ente
care c
al)
h care
admi
as tra
r, priv
l conta
is not
act on
r facil
s tran
om an
acute
outsid
e faci
:
dicalincluded in the dataset. In fact, the ACS CAD clinical data
PA
N
D
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Element Name Element Definition
rior angina History of angina before the current admission. “Angina” refers to evidence or knowledge of symptoms before this acute
event described as chest pain or pressure, jaw pain, arm pain, or other equivalent discomfort suggestive of cardiac
ischemia. Indicate if angina existed 2 wk before admission and/or within 2 wk before admission.
verage number of episodes of
angina in the prior week
Average number of distinct episodes of anginal pain that occurred in the last week before hospital admission or this visit
umber of angina episodes in
the prior 6 wk
Total number of distinct episodes of anginal pain that occurred in the last 6 wks before hospital admission or visit should be
recorded. Duration of each episode and requirement for sublingual nitroglycerin are also documented.
Intermittent claudication History of claudication that typically presents as exertional fatigue, cramping, or aching in the muscles of the legs that is
reproducible and resolves promptly with rest. Choose 1 of the following:
● Yes
● No
Prior MI Indicate if the patient has had at least one documented previous myocardial infarction. Any occurrence between birth and
arrival at first facility. The term acute MI should be used when there is evidence of myocardial necrosis in a clinical
setting consistent with myocardial ischemia. Under these conditions, any 1 of the following criteria meets the diagnosis
for MI:
● Detection of the rise and/or fall of cardiac biomarkers (preferably cTn) with at least 1 value above the 99th percentile and
with at least 1 of the following:
- Symptoms of ischemia
- New or presumed new significant ST-T changes or new LBBB
- Development of pathological Q waves on the ECG
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
- Identification of an intracoronary thrombus by angiography or autopsy
● Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic
changes or new LBBB, but death occurred before cardiac biomarkers were obtained or before cardiac biomarker values
would be increased.
● PCI-related MI is arbitrarily defined by elevation of cTn values (5 times the 99th percentile URL) in patients with normal
baseline values (99th percentile URL) or a rise in cTn values 20% if baseline values are elevated and stable or
falling; in addition, either symptoms suggestive of myocardial ischemia OR NEW ISCHEmic electrocardiographic
changes or angiographic findings consistent with a procedural complication or imaging demonstration of new loss of
viable myocardium or new regional wall motion abnormality.
● Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial
ischemia and with a rise and/or fall of cardiac biomarker values with at least 1 value 99th percentile URL.
● CABG-related MI is arbitrarily defined by elevation of cardiac biomarker values (10 times the 99th percentile URL) in
patients with normal baseline cTn values (99th percentile URL) plus either new pathological Q waves or new LBBB, or
angiographically documented new graft or new native coronary artery occlusion, or imaging evidence of new loss of
viable myocardium.
● The 99th percentile is observed after the procedure in conjunction with symptoms suggestive of myocardial ischemia or
new ischemic electrocardiographic changes or angiographic findings consistent with a procedural complication or
imaging demonstration of new loss of viable myocardium or in patients with a preprocedure elevated biomarker that is
stable or falling, a rise of biomarker values 20% in conjunction with the PCI-related criteria stated above.
A prior MI can also be documented if the patient has any 1 of the following criteria that meets the diagnosis for prior MI:
● Pathological Q waves with or without symptoms in the absence of nonischemic causes
● Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a
nonischemic cause
● Pathological findings of a prior MI
Previous history of heart
failure
Indicate if there is a previous history of heart failure before this care encounter. A previous hospital admission with the
principal diagnosis of heart failure is considered evidence of a history of heart failure.
Heart failure is defined as physician documentation or report of any of the following clinical symptoms of heart failure
described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention, or
the description of rales, jugular venous distention, pulmonary edema on physical examination, or pulmonary edema on
chest x-ray. A low ejection fraction without clinical evidence of heart failure does not qualify as heart failure.
NYHA functional class If heart failure is present, indicate the NYHA functional class.
Choose 1 of the following:
● Class I: patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does
not cause undue fatigue, palpitation, or dyspnea.
● Class II: patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Ordinary physical activity results in fatigue, palpitation, or dyspnea.
● Class III: patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less
than ordinary activity causes fatigue, palpitation, or dyspnea.
● Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms
are present even at rest or minimal exertion. If any physical activity is undertaken, discomfort is increased.
Prior PCI Indicate if the patient had a previous PCI (even if unsuccessful) of any type (balloon angioplasty, stent, or other), performed
before the current admission.
Check all that apply:
● None
● Balloon angioplasty
● Bare metal stent
● Drug-eluting stent
● Other
Note: Timeframe does NOT include the current admission.
ate of prior PCI If the patient had a previous PCI of any type (balloon angioplasty, stent, or other) performed before the current admission,
indicate the date of the most recent PCI. If month or day is unknown, year is sufficient.
PE
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Element Name Element Definition
rior CABG Indicate whether the patient had a previous CABG surgery before the current admission.
Note: Timeframe does NOT include the current admission.
Date of prior CABG If the patient had a previous CABG before the current admission, indicate the date of the most recent CABG. If month or day is
unknown, year is sufficient.
Prior catheterization with
stenosis >50%
The patient has documented CAD at coronary angiography at any time before the current admission, with at least a 50%
stenosis in the diameter of a major coronary artery. If the patient had a cardiac catheterization before the index event
that demonstrated a stenosis of 90% that was successfully stented to a 0% residual, this should be coded as “yes,”
because a stenosis 50% diameter was documented.
Cerebral artery disease Current or previous history of any of the following:
● Ischemic stroke: an acute episode of focal, cerebral, spinal, or retinal dysfunction caused by infarction of the central nervous
system tissue
● TIA: transient episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal ischemia without
acute infarction
● Noninvasive or invasive arterial imaging test demonstrating 50% stenosis of any of the major extracranial or intracranial
vessels to the brain
● Previous cervical or cerebral artery revascularization surgery or percutaneous intervention
This does not include chronic (nonvascular) neurological diseases or other acute neurological insults such as metabolic and
anoxic ischemic encephalopathy.
Prior stroke Indicate whether the patient has a history of stroke, which is defined as an acute episode of neurological dysfunction caused
by focal or global brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.
If present, record type of stroke:
● Ischemic stroke
● Intracerebral hemorrhage
● Subarachnoid hemorrhage
● Unknown type
If ischemic, list the most likely etiologies:
● Large artery atherosclerosis of the extracranial vessels (e.g., carotid)
● Large artery atherosclerosis of the intracranial vessels (e.g., middle cerebral artery stenosis)
● Cardioembolism
● Small vessel occlusion (lacunar)
● Ischemic stroke of other determined etiology (e.g., arterial dissection)
● Ischemic stroke of undetermined etiology
PAD Current or previous history of PAD (includes lower extremity from iliac to tibials and upper extremity with subclavian and
brachials. Excludes renal, coronary, cerebral, and mesenteric vessels and aneurysms.) This can include
● Claudication on exertion that is relieved by rest
● Amputation for severe arterial vascular insufficiency
● Vascular reconstruction, bypass surgery, or percutaneous revascularization in the arteries of the lower and upper extremities
● Positive noninvasive test (e.g., ankle brachial index 0.9, ultrasound, MR imaging or CT scanning of 50% diameter stenosis
in any peripheral artery [i.e., subclavian, femoral, iliac]) or angiographic imaging
Aorta disease Current or previous history of disease of the thoracic, thoracoabdominal, or abdominal aorta (typically aneurysm)
Renal artery disease Current or previous history of disease of the main renal arteries or extrarenal branches
History of alcohol
consumption/dependency
Specify alcohol consumption history. Choose from the following categories:
● None
● 1 alcoholic drink per week
● 2–7 alcoholic drinks per week
● 8 alcoholic drinks per week
Specify alcohol dependency history. Choose all that apply:
● Documented alcohol dependency
● Medical sequelae of alcohol consumption (alcoholic hepatitis, cirrhosis, alcohol neuropathy, Wernicke-Korsakoff syndrome)
● Treatment for alcohol dependency
For patients with alcohol dependency, note treatment for dependency, cessation of use, or continued use.
rectile dysfunction Indicate if the patient has a history of erectile dysfunction.
Choose 1 of the following:
● Yes
● No
● Unknown
● N/A
Depression Current or previous diagnosis of depression or documentation of a depressed mood or affect
Diabetes History of diabetes diagnosed and/or treated by a healthcare provider. The American Diabetes Association criteria (33) include
documentation of the following:
1. Hemoglobin A1c 6.5%; or
2. Fasting plasma glucose 126 mg/dL (7.0 mmol/L); or
3. 2-h Plasma glucose 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test; or
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose 200 mg/dL
(11.1 mmol/L)
This does not include gestational diabetes.
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Element Name Element Definition
iabetes control Indicate the patient’s diabetes control method as presented on admission. Patients placed on a preprocedure diabetic
pathway of insulin drip at admission but whose diabetes was controlled by diet or oral methods are not coded as being
treated with insulin.
Choose the most aggressive therapy from the order below
● Insulin: insulin treatment (includes any combination with insulin)
● Other subcutaneous medications (e.g., GLP-1 agonist)
● Oral: treatment with oral agent (includes oral agent with or without diet treatment)
● Diet only: Treatment with diet only
● None: no treatment for diabetes
● Other: other adjunctive treatment, non-oral/insulin/diet
Hypertension Indicate if the patient has a current diagnosis of hypertension defined by any 1 of the following:
● History of hypertension diagnosed and treated with medication, diet, and/or exercise
● Prior documentation of blood pressure 140 mm Hg systolic and/or 90 mm Hg diastolic for patients without diabetes or
chronic kidney disease, or prior documentation of blood pressure 130 mm Hg systolic or 80 mm Hg diastolic on at
least 2 occasions for patients with diabetes or chronic kidney disease
● Currently undergoing pharmacological therapy for treatment of hypertension
Tobacco use (34) Current or previous use of any tobacco product, including cigarettes, cigars, pipes, and chewing tobacco, captured as smoking
status:
● Current everyday smoker
● Current some day smoker
● Former smoker
● Never smoker
● Smoker, current status unknown
Illicit drug use Documented history of current, recent, or remote abuse of any illicit drug (e.g., cocaine, methamphetamine, marijuana) or
controlled substance.
Dyslipidemia Indicate if the patient has a history of dyslipidemia that was diagnosed and/or treated by a physician. NCEP criteria include
documentation of the following:
● Total cholesterol 200 mg/dL (5.18 mmol/L); or
● LDL 130 mg/dL (3.37 mmol/L);
● HDL 40 mg/dL (1.04 mmol/L) in men and 50 mg/dL (1.30 mmol/L) in women;
● Currently receiving antilipidemic treatment
Family history of premature
CAD
Indicate if the patient has any direct blood relatives (parents, siblings, children) who have had any of the following at age
55 y for male relatives or 65 y for female relatives:
● Angina
● Acute MI
● Sudden cardiac death without obvious cause
● CABG surgery
● PCI
Previous implantation of a
pacemaker or ICD
Indicate if the patient had a pacemaker or ICD implanted before the current encounter.
Information about the type of device (pacemaker, biventricular/resynchronization/CRT, ICD, combination), cardiac chamber(s)
involved, and year of implantation may be helpful.
Prior atrial fibrillation or flutter Indicate whether atrial fibrillation or flutter is present within 2 wk before admission.
Whether or not the patient is currently experiencing atrial fibrillation or flutter should also be noted.
History of influenza
immunization
Indicate if the patient has a history of influenza immunization. The month and year of the most recent immunization should be
noted.
History of pneumococcal
immunization
Indicate if the patient has a history of pneumococcal immunization. The month and year of the most recent immunization
should be noted.
Current dialysis Indicate if the patient currently requires dialysis treatment, including hemodialysis or peritoneal dialysis.
Angina grade Indicate grade symptoms or signs in patients with suspected or presumed stable angina (or anginal equivalent) according to
the CCS grading scale (35):
● Class I: ordinary physical activity, such as walking or climbing stairs, does not cause angina. Angina occurs with strenuous,
rapid, or prolonged exertion at work or recreation.
● Class II: slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or
climbing stairs after meals, or in cold, in wind, or under emotional stress, or only during the few hours after awakening.
Angina occurs on walking 2 blocks on the level and climbing 1 flight of ordinary stairs at a normal pace and in
normal conditions.
● Class III: marked limitation of ordinary physical activity. Angina occurs on walking 1 to 2 blocks on the level and climbing
1 flight of stairs in normal conditions and at a normal pace.
● Class IV: inability to perform any physical activity without discomfort—angina symptoms may be present at rest.
Amount of sublingual
nitroglycerin consumed
Record the number of sublingual nitroglycerin tablets or spray used each week for symptomatic episodes. Record prophylactic
usage also. Average the total number of sublingual uses over the 6-wk interval and record the weekly range.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CCC, Canadian Cardiovascular Society; cTn, cardiac troponins; CRT, cardiac resynchronization therapy; CT, computed
tomography; ECG, electrocardiogram; GLP-1, glucagon peptide-like-1; HDL, high-density lipoprotein; ICD, implantable cardioverter-defibrillator; LBBB, left bundle-branch block; LDL, low-density lipoprotein;
MI, myocardial infarction; MR, magnetic resonance; N/A, not available; NCEP, National Cholesterol Education Program; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI,
percutaneous coronary intervention; TIA, transient ischemic attack; and URL, upper reference limit.
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registry. For example, the AR-G includes 81 of the data
elements discussed in this document.
Third, the use of standardized definitions and registry
data should facilitate quality improvement by collecting
data on these data elements as part of a quality-
improvement program at a hospital, state, or national
level and thereby improve both the process of care and
clinical outcomes.
Fourth, these data elements and definitions can be used in
the development of performance measures by identifying
underutilization of therapies (24–27). They could be used to
compare various subgroups of patients in the various per-
formance measures and to identify certain groups for whom
medications are underused (e.g., the GWTG age and
gender paper). These elements would also fit very well with
longitudinal follow-up studies, where the same definitions
could be used by hospitals and outpatient providers to
monitor a patient’s adherence to medication and clinical
course.
Fifth, the list of data elements and definitions could
become the basis for developing a standardized charting
process with the anticipation that medical charting used in
the process of delivering care could progressively move
toward an electronic format. The specifics of coding ele-
ments in EHRs are a large and evolving area. Many other
groups are working on this; details are beyond the scope of
this document but would need to be provided before
implementation.
Sixth, appropriate collection of confounding characteris-
tics will allow adjustment for comorbidities and other
variables that may affect outcomes and quality metrics
between different providers, hospitals, and geographical
networks and ensure scientific comparisons.
Finally, considering the application of these data ele-
ments to use in the real-world setting, the writing commit-
tee paid close attention to the level of detail required to fully
describe certain variables, such as timing of prior cardiovas-
cular events, timing of procedures, specific drug names
versus classes of drugs, and types of insurance. The com-
mittee agreed that for these or any of the data elements
listed, the user can decide to collect more or less informa-
tion, depending on the circumstance. For example, if a
hospital association were compiling a registry to assess the
relationship of patient insurance status with use of cardiac
procedures and their outcomes, the group might elect to use
more subcategorizations than listed in this document. On
the other hand, if a pharmaceutical company were doing a
study to evaluate the use of a new drug for UA, type of
insurance might not matter and could be omitted. A third
example would be if a community hospital wished to track
its use of new therapies, such as new antiplatelet agents, for
which as few as 10 of the listed elements might be
collected on patients. Thus, this listing of data elements
and definitions could be expanded or condensed to meet
the needs of the study or project in which they are beingused. However, the users would not want to adapt the
individual definitions since that would no longer allow
direct comparison of these elements to other studies
using these standard definitions.
These data elements could also be expanded to include
additional information, such as all the detailed relative
contraindications to aspirin or beta blockers or for careful
measurement of performance measures, as was done in the
Cooperative Cardiovascular Project (28). Expansion of the
variables collected would also be expected in the setting of a
randomized clinical trial of a new drug, for which more
information would be required on additional study proce-
dures and drug therapies. Thus, depending on the intended
use of the variables, the number of data elements used could
be restricted or expanded. In either case, the definitions
provided in this document should assist in standardizing the
process. It should also be noted that other data elements and
measures may be important in the assessment of patients
with ACS. For example, quality-of-life measures such as the
Seattle Angina Questionnaire (29) and the Medical Out-
comes Study 36-Item Short Form Health Survey (SF-36)
(30) have been used extensively in the evaluation of outcome
in cardiac patients. Those developing registries and per-
forming clinical trials are encouraged to adopt a similar
approach in evaluating and choosing measures so that these
efforts will be more easily integrated into future data
standards for patients with ACS.
3. ACS and CAD Clinical Data Standard
Elements and Definitions
3.1. Demographic and Admission Data Elements
There are 5 demographic data elements that include the
patient’s sex, date of birth, race, and ethnicity, and the postal
code for the patient’s residence. It is intended that these
elements be collected once for each patient. The race and
ethnicity data elements are defined in a way that is consis-
tent with the standard formats suggested by the U.S.
Department of Health and Human Services, which includes
identification of Hispanic or Latino ethnicity. The postal
code for the patient’s residence is included to permit
geographical analysis of results and comparison with other
cardiovascular registry data analyses.
Sixteen data elements and definitions describe the status
of care for the current data collection (inpatient or outpa-
tient); for inpatients, details include date of admission,
source of admission, information about payment type,
information about first medical contact, date and time of
arrival and transfer to an outside facility, mode of transport
to the local facility, and location and time of first evaluation
in the local facility. These data elements define the critical
aspects of timing and level of acuity for the presentation of
this patient to the healthcare system. They provide the
initial elements of information that articulate risk for the
patient and the impact of these factors on the entire episode
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source and type have been standardized in recent recom-
mendations by the Centers for Medicare & Medicaid
Services and The Joint Commission.
3.2. History and Risk Factors Data Elements
Assessment of the patient’s cardiovascular and general
medical history is necessary for assessing risk and for a fuller
understanding of variations in outcome. The information is
also critical in applying these results to targeted quality-
improvement efforts and for comparison of these data with
clinical trial results. Many of the data elements in this
section (Table 2) are common to risk models that have been
developed to predict outcome in patients undergoing PCI
and cardiac surgery (31). The element capturing the history
of MI (and all data elements in this dataset referring to MI)
incorporates the recent elements for the universal definition
of MI (22). Definitions and categorization of stages of heart
failure follow recent recommendations proposed by the
ACCF/AHA data standards document on heart failure (4).
The definitions for peripheral arterial disease were taken
from recent work by the Peripheral Atherosclerotic Vascular
Disease Data Standards document (32). The writing com-
mittee attempted to include only data elements that were
pertinent to characterizing the risk of the patient. In
addition, specific coding descriptors and detailed definitions
have been provided so that medical abstractors should be
able to code most of these data elements with information
that is available as part of the standard process of document-
ing the delivery of care. Software and applications are now
being developed to automatically pull information on some
data elements from EHRs. It would be optimal if the
algorithms these programs use could follow the standard
definitions.
3.3. Clinical Presentation Data Elements
Clinical presentation data elements (Table 3) include the
date and time of symptom onset, the presence of positive
biomarkers (troponin I or T, CK-MB, or bedside troponin)
within the first 24 hours of initial presentation that exceed
the locally defined upper limits of normal, heart failure on
first medical contact, height, weight, waist circumference,
Killip class, heart rate, systolic blood pressure on first
medical contact, angina type with number of episodes and
possible secondary causes, and syncope. Presenting symp-
toms are well described in the data definition and along with
the presence of biomarkers are key indicators for defining
the patient with ACS. Height and weight are important
parameters in calculating body surface area and determining
whether pharmacological dosing was therapeutic or above
acceptable thresholds. Killip class has been a useful classi-
fication system and is included with specific criteria for
determination of the appropriate level.3.4. Diagnostic Procedure Data Elements
Findings on the ECG provide the most important infor-
mation in stratifying patients as those with STEMI and
those with NSTEMI. Because it is becoming more com-
mon for emergency medical services personnel to perform a
prehospital 12-lead ECG on initial contact with a patient
with suspected MI or ACS in the field, data elements are
included to track the date, time, and location of the first
ECG. The data definition provides detailed criteria for
categorizing electrocardiographic findings as ST-segment
elevation, new left bundle-branch block, or isolated infero-
basal MI. Location of electrocardiographic changes and
other pertinent findings (new ST-segment depression, new
T-wave inversion, etc.) are collected. Data elements are also
included for laboratory tests that are routinely performed on
patients with CAD, including total cholesterol, low-density
lipoprotein, high-density lipoprotein, and triglycerides.
Other laboratory values supporting the evaluation of cardiac
function, metabolic syndrome, and liver and renal function
(brain natriuretic peptide, glucose, hemoglobin A1c, hemat-
ocrit, and creatinine) are collected and provide easily ob-
tained information that characterizes the patient’s general
status and gives data that can be used to further risk-stratify
patient outcomes. Table 4 includes troponin, creatinine ki-
nase (CK) and creatinine kinase–MB isoenzyme (CK-MB)
with first and peak levels for these markers. However, if more
precision on timing of CK-MB is desired, the full set of these
markers could be collected with dates and times so as to ensure
being able to distinguish initial biomarker elevation versus
post-PCI elevations.
3.5. Invasive Therapeutic Intervention
Data Elements
Many clinical trials have been conducted to establish
effective therapeutic approaches for the treatment of ACS
as well as studies that have identified optimal timing for
invasive strategies based on risk stratification of the
patient (36 –38). The invasive therapeutic interventions
section (Table 5) includes data elements covering nonin-
vasive stress testing, results of evaluation of maximum
stenosis percent narrowing in the major epicardial sys-
tems, assessment of left ventricular ejection fraction and
the modality used for this measurement, and results of
diagnostic coronary angiography if performed (definition
of the culprit artery, TIMI flow in the culprit artery, and
stenoses in the major coronary artery systems). Because
primary PCI has been established as the preferred revas-
cularization approach for patients with STEMI and an
early invasive strategy as the most effective strategy for
patients with NSTEMI, data elements are included that
capture the time of arrival at the catheterization labora-
tory, first device activation date, and time for calculating
door-to-balloon time for patients with STEMI, which
has been related to improved immediate and long-term
outcomes in these patients (21,39,40) An important data
lmonar
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drug-eluting, or other) and the number of stents used.
Data elements are included that provide important mod-
ifiers that may occur in the treatment of these patients,
including reasons for delay in performing PCI and
reperfusion contraindications. Given that other signifi-
cant therapeutic approaches may occur during hospital-
ization, data elements are included to track any peripheral
Table 3. Clinical Presentation Data Elements and Definitions
Element Name
Symptom onset date/time Indicate the date and time the patient fi
ischemic symptoms, record the
Symptoms may include jaw pain
equivalent discomfort suggestiv
which symptoms became const
Heart failure on first medical
contact
Indicate if there is physician documenta
Heart failure is defined as physician doc
described as unusual dyspnea o
the description of rales, jugular
chest x-ray. A low ejection fracti
Note: Killip class 2 is defined as rales o
rales over 50% of the lung fie
Killip class Indicate the patient’s Killip class at the
● Class 1: absence of rales over the lung
● Class 2: rales over 50% of the lung fi
● Class 3: rales over 50% of the lung fi
● Class 4: shock
Heart rate Indicate the first measurement or earlie
from the transferring facility is a
Systolic blood pressure on
first medical contact
Indicate the first measurement or earlie
care. Measurement from the tra
Angina type Indicate the category of the patient’s ty
● I. Atypical chest pain: pain, pressure, o
consistent with pain or discomfo
● II. Stable angina: angina without a cha
by rest and/or sublingual/oral/t
● III. ACS (choose 1 of the following):
- A. UA: The patient was hospitalized
One of the following criteria is n
1. Angina that occurred at rest and
2. New-onset angina of at least CCS
3. Recent acceleration of angina re
patient must also not have any
- B. MI: For a complete definition, plea
Number of episodes of angina
in the past 24 h
Indicate the number of distinct episodes
Secondary cause of angina
(yes/no)
Note whether angina was precipitated b
or severe valvular disease as de
Cardiac arrest at first
medical contact
Indicate if the patient has had an episo
external defibrillation attempts
or ED personnel or 2) were puls
Choose 1 of the following:
● Yes
● No
Note: [Sudden] cardiac arrest is the sud
breathing and no signs of circul
sudden death. Cardiac arrest sh
and/or defibrillation or cardiove
that are not fatal.
Height Indicate the patient’s first recorded heig
Weight Indicate the patient’s weight in kilogram
Waist circumference Indicate waist circumference based on t
measurement after inspiration a
between the lowest rib and the
ACS indicates acute coronary syndromes; CCS, Canadian Cardiovascular Society; CPR, cardiopu
services; MI, myocardial infarction; and UA, unstable angina.vascular or cerebrovascular interventions, requirement forCABG surgery, use of a pulmonary artery catheter, and
more advanced therapeutic techniques, including place-
ment of an intra-aortic balloon pump, ventilator, and
enhanced external counterpulsation support.
3.6. Medications Table of Data Elements
The efficacy of pharmacological therapy at symptom onset,
throughout hospitalization, and at discharge from the hos-
Element Definition
ted ischemic symptoms lasting 10 min. If the patient had intermittent
nd time of the most recent ischemic symptoms before hospital presentation.
pain, shortness of breath, nausea, vomiting, fatigue/malaise, or other
n MI. In the event of stuttering symptoms, ACS symptom onset is the time at
quality or intensity.
r a report of heart failure on the first medical contact.
tation or report of any of the following clinical symptoms of heart failure
t exertion, recurrent dyspnea occurring in the supine position, fluid retention; or
s distention, pulmonary edema on physical exam, or pulmonary edema on
hout clinical evidence of heart failure does not qualify as heart failure.
0% of the lung fields or the presence of an S3. Killip class 3 is defined as
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f hospital admission:
and absence of S3
r the presence of an S3
ord of heart rate (in beats per minute) for this episode of care. Measurement
able.
ord of systolic blood pressure (in millimeters of mercury) for this episode of
ing facility is acceptable.
ngina if present. Choose 1 of the following:
omfort in the chest, neck, or arms not clearly exertional or not otherwise
myocardial ischemic origin.
frequency or pattern for the 6 wk before this procedure. Angina is controlled
taneous medications.
documented in the medical record with serial ECGs and biochemical profiles.
ary:
rolonged, usually lasting 10 min
ification III severity
d by an increase in severity of at least 1 CCS class to at least CCS class III. The
mical evidence of myocardial necrosis.
e “MI” in the “Outcomes” section.
ginal pain that occurred in the past 24 h before hospital admission.
condary factor such as fever, anemia, hypoxemia, tachycardia, thyrotoxicosis,
by Braunwald.
ardiac arrest evaluated by EMS or ED personnel and either 1) received
responders or emergency personnel) or chest compressions by organized EMS
but did not receive defibrillation attempts or CPR by EMS personnel.
ssation of cardiac activity. The victim becomes unresponsive with no normal
If corrective measures are not taken rapidly, this condition progresses to
e used to signify an event as described above that is reversed, usually by CPR
r cardiac pacing. Sudden cardiac death should not be used to describe events
entimeters on admission/encounter to your facility.
est to the date of admission/encounter.
erage of 2 measurements made while the patient is standing. Take 1
other after expiration. Measurements should be taken at the midpoint
rest. Indicate in centimeters.
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Element Name Element Definition
Electrocardiography
Rhythm The categories of rhythm are
● Sinus rhythm
● Atrial fibrillation (or flutter)
● Paced
● Other rhythm (e.g., VT, supraventricular tachycardia)
Site where first ECG
obtained
Indicate where the first ECG was obtained.
Choose 1 of the following:
● Prehospital (i.e., in ambulance): Check if the first ECG was obtained before arrival at your hospital, either during ground
transport by EMS, air ambulance, or other method of critical care transport.
● On arrival to the first hospital where the patient presented: Check if the first ECG performed after the most recent ischemic
episode before hospital presentation was obtained on arrival at the first hospital where the patient presented.
● Private physician office or outpatient clinic
● Hospital inpatient unit
First ECG date/time Indicate the date and time of the first ECG.
STEMI or STEMI
equivalent
Indicate if there was either new or presumed new ST-segment elevation, new LBBB, or isolated inferobasal MI before any
procedures and not more than 24 h after the initial presentation.
ECG evidence for STEMI
or STEMI equivalent
Indicate if there was either new or presumed new ST-segment elevation, new LBBB, or isolated inferobasal (posterior) MI noted on
the ECG before any procedures and not more than 24 h after the initial presentation. Choose 1 of the following:
● New ST-segment elevation at the J point in 2 contiguous leads with the cutpoints 0.1 mV in all leads other than leads V2 through V3,
where the following cutpoints apply:0.2 mV in men age40 y,0.25mV in men age40 y, or0.15mV in women
● New isolated ST-segment depression 0.1 mV in at least 2 contiguous leads of V1 through V3 with upright T waves
● New ST-segment elevation 0.05 mV in leads V7 through V9 or 0.1 mV in men age 40 y (inferobasal [posterior] infarction)
● New ST-segment elevation 0.05 mV (0.1 mV in men age 30 y) in leads V3R, V4R (right ventricular infarction)
● New ST-segment elevation 0.1 mV in lead aVR with concomitant ST-segment depression 0.05 mV in at least 2 contiguous
leads
TEMI or STEMI
equivalent noted
Indicate if a STEMI or STEMI equivalent was noted on either the first or a subsequent ECG. The subsequent ECG must be
performed within 24 h of initial presentation, either to your facility or the transferring facility if a transfer patient.
Choose 1 of the following:
● First ECG
● Subsequent ECG
STEMI or STEMI
equivalent date/time
Indicate the date and time of the earliest subsequent ECG with ST-segment elevation, LBBB, or isolated inferobasal MI.
Other ischemic ECG
findings
Indicate if other findings from the ECG were demonstrated within 24 h of the first medical contact.
Choose all that apply:
● New or presumed new ST-segment depression: Indicate if there was new or presumed new horizontal or downsloping ST
depression 0.05 mV in 2 contiguous leads and/or T inversion 0.1 mV in 2 contiguous leads with prominent R wave or
R/S ratio 1. T-wave negativity may be normal in leads with predominant negative QRS complexes (see discussion) but are
usually abnormal when the QRS complex is upright.
● New or presumed new T-wave inversion: Indicate if there was a new or presumed new T-wave inversion of at least 0.1 mV in
2 contiguous leads. The T wave usually has a polarity of the T-wave vector similar to the QRS vector. Thus, in normal subjects,
negative T waves may be observed when the QRS is negative (e.g., lead aVL with vertical axis). Juvenile T-wave patterns,
marked pectus excavatum, and other conditions may also be associated with T-wave inversion that is not ischemic in origin.
● Transient ST-segment elevation lasting 20 min: Indicate if there was new or presumed new ST-segment elevation at the J point
in 2 contiguous leads with the cutpoints 0.1 mV in all leads other than leads V2 through V3, where the following cutpoints
apply: 0.2 mV in men age 40 y, 0.25 mV in men age 40 y, or 0.15 mV in women.
● Indicate if a new persistent LBBB was present.
● None of the above: Indicate if the first ECG did not reveal ST-segment depression, transient ST-segment elevation, or T-wave
inversion.
ocation of ECG
changes
The location of each type of electrocardiographic change listed below can be divided into 4 categories:
● Inferior leads: II, III, aVF
● Anterior leads: V1 through V6
● Lateral leads: I, aVL,
● True posterior (inferobasal): (relevant only for tall wide R waves 40 ms in leads V1 and V2
Consideration can be given to recording posterior ST changes, the maximal amount of ST (if applicable), and/or the number of
leads with ST.
BB and type The presence of left or right BBB should be noted, as well as whether it is new, old, or of uncertain timing.
ollow-up ECG: new Q
waves
If a follow-up ECG is performed (at least 6 h after the initial ECG), the presence or absence of new Q waves that are 0.03 s in
width, in at least 2 contiguous leads, and 1 mm (0.1 mV) in depth not seen on the initial ECG should be noted, as well as
the location described above.
aboratory Tests
DL value Indicate the value of the LDL cholesterol. If the value is reported using a “” symbol (e.g., 300), record the number only (e.g., 300).
Lipids obtained within the first 24 h of this admission should take precedence. If24 h after admission, then enter prior values.
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lant therapies are crucial in managing the cascade of
thrombotic events that occur with ACS. The complexity
of the pathways involved with this cascade has led to the use
of multiple therapeutic agents. Aspirin, anticoagulant
agents, including heparin and bivalirudin, clopidogrel, and
GP IIb/IIIa inhibitors have been established as essential for
Table 4. Continued
Element Name
HDL value Indicate the HDL-cholesterol value. If the valu
Lipids obtained within the first 24 h of th
values.
riglycerides value Indicate the value of triglycerides. If the value
obtained within the first 24 h of this adm
ate of lipids Indicate the date the sample was collected (n
hospitalization” or “Unknown.” Lipids ob
admission, then enter prior values.
hen lipids were
measured: other
Indicate the date and time the sample was co
hospitalization” or “Unknown.” Lipids ob
admission, then enter prior values.
NP/NT-proBNP value Indicate the results from first BNP or first NT
specify which assay type was done.
s-CRP Indicate the value of the first serum hs-CRP le
lucose Indicate the first glucose value taken. Indicate
reatinine Indicate the creatinine value taken at the tim
emoglobin Indicate the value and units for the first hemo
indicated.
emoglobin A1c value Indicate the percentage value for the first hem
also be indicated.
NR Indicate the numerical value of INR on admis
nitial CK value Indicate the results of the first CK sample obt
hospital. If the patient was transferred in
precedence.
eak CK value Indicate the results of the peak CK sample ob
K ULN Indicate the total CK ULN as defined by indivi
kCat/L) should be noted.
nitial CK-MB value Indicate the initial CK-MB value. The initial sa
from a transferring hospital or your hosp
should take precedence.
K-MB ULN Indicate the initial CK-MB sample ULN for the
Examples:
1. Reference range given as 0-5: Record ULN
2. ULN given as 5: Record ULN as 5
The initial sample value refers to the first sam
hospital. If the patient was transferred, d
eak CK-MB value Indicate the results of the highest sample obt
Note: Enter the value. If the value is reported
nitial troponin value Indicate the results of the first sample obtain
the patient was transferred, data availab
Note: Enter the value. If the value is reported
roponin type Indicate which type:
● Type T
- Indicate if high sensitivity
● Type I
- Indicate if high sensitivity
Peak troponin value Indicate the results of the highest sample obt
Note: Enter the value. If the value is reported
BBB indicates bundle branch block; BNP, brain natriuretic peptide; CK, creatinine kinase; CK-M
high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; INR, international normalized
N-terminal prohormone of brain natriuretic peptide; STEMI, ST-segment elevation myocardial infthe management of patients with ACS. The writing com-mittee determined that where possible, collection of detailed
data on medications (Table 6) would provide information
that is critical to evaluate patient outcomes. The group
determined that the important dimensions of medication
administration were the type of agent used, timing (given
within the first 24 hours, during hospitalization, at discharge,
and during the months after hospital discharge), dosage,
Element Definition
ported using a “” symbol (e.g., 300), record the number only (e.g., 300).
mission should take precedence. If 24 h after admission, then enter prior
orted using a “” (e.g, 300), record the number only (e.g., 300). Lipids
n should take precedence. If 24 h of admission, then enter prior values.
date and time results reported) OR check either “Performed before
within the first 24 h of this admission should take precedence. If 24 h after
d (not the date and time results reported) OR check either “Performed before
within the first 24 h of this admission should take precedence. If 24 h after
P performed during this admission. If done, enter the numerical value and
d units.
ting or not.
dmission and at the time of discharge.
collected during this admission. Date and time of collection should also be
in A1c collected during this admission. Date and time of collection should
ate and time of collection should also be indicated.
within the first 24 h of care, either from a transferring hospital or your
ur hospital, data available from the transferring facility should take
during this admission.
ospital laboratory standards. The units of CK and type of units (e.g., IU, ng/dL,
value refers to the first sample obtained within the first 24 h of care, either
the patient was transferred, data available from the transferring facility
If a range is given, record the highest number in the range.
btained within the first 24 h of care, either from a transferring hospital or your
vailable from the transferring facility should take precedence.
during this admission.
a “” symbol (e.g., “0.02”), record the number only (e.g., “0.02”).
hin the first 24 h of care, either from a transferring hospital or your hospital. If
m the transferring facility should take precedence.
a “” symbol (e.g., “0.02”), record the number only (e.g., “0.02”).
during this admission.
a “” symbol (e.g., “0.02”), record the number only (e.g., “0.02”).
tinine kinase MB isoenzyme; ECG, electrocardiogram; EMS, emergency medical services; HDL,
BB, left bundle-branch block; LDL, low-density lipoprotein; MI, myocardial infarction; NT-proBNP,
VT, ventricular tachycardia; and ULN, upper limit of normal.e is re
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Element Name Element Definition
acemaker implantation If a pacemaker was placed during this admission, indicate what type of device:
● Single chamber
● Dual chamber
● CRT
● CRT-D
● CRT-P
● Biventricular
● Pacer
emporary pacemaker Temporary pacemaker placed during this admission
CD An ICD may be placed for:
● VF
● Symptomatic VT
● Asymptomatic VT
● Other (specify)
● Inducible VT/VF at electrophysiological study
● Syncope
● Primary prevention for patients in high-risk heart failure group
The brand, model number, and serial number of the device may be recorded.
oninvasive stress testing Indicate if the patient underwent exercise or pharmacological stress testing with or without echocardiographic or radionuclide
imaging.
ate of noninvasive stress
testing
Indicate the date of exercise or pharmacological stress testing with or without echocardiographic or radionuclide imaging.
oninvasive angiogram Indicate if the patient underwent 1 of the following:
● MR angiogram
● Multislice CT scan
aximum stenosis by vessel
(LAD, LCx, RCA, LM, graft)
Stenosis represents the percentage occlusion, from 0% to 100%, associated with the identified vessel systems. Percent stenosis at
its maximal point is estimated to be the amount of reduction in the diameter of the “normal” vessel proximal to the lesion.
For the denominator, take the maximum internal lumen diameter proximal and distal to the lesion. In instances where
multiple lesions are present, enter the highest percentage stenosis noted. The systems of interest are as follows and should
include major branch vessels of 2 mm diameter:
● Greatest stenosis assessed in the LAD or any major branch vessel
● Greatest stenosis assessed in the LCx or any major branch vessel
● Greatest stenosis assessed in the RCA or any major branch vessel
● Greatest stenosis assessed in the LM
● Greatest stenosis assessed in bypass graft
aximal or submaximal
stress test
Maximal stress test (symptom limited) or submaximal test (e.g., modified Bruce protocol ending with stage 1 or stage 2)
schemia result (positive,
negative, equivocal,
nondiagnostic test)
● Positive: new exercise-induced ischemic horizontal or downsloping ST-segment depression 0.10 mV or new ST-segment
elevation 0.10 mV in a noninfarct territory, as compared with the baseline tracing (in the absence of electrocardiographic
confounding such as LV hypertrophy, digoxin-induced changes, or LBBB)
● Negative: normal exercise test. No significant exercise-induced ST shift or chest pain suggestive of angina and a normal
hemodynamic response to exercise with adequate workload to test cardiac reserve.
● Equivocal: exercise-induced chest pain considered to be angina in the absence of significant ischemic ST change.
● Nondiagnostic test: negative as defined above, but level of exercise insufficient to adequately test cardiac reserve (e.g., 85% of
age-predicted maximum heart rate achieved) or exercise-induced electrocardiographic changes in the presence of LBBB, LVH,
or other known confounders.
VEF assessed Indicate whether the patient had LVEF assessed via invasive (i.e., LV gram) or noninvasive (i.e., echo, MR, CT or nuclear) testing
before or during the admission.
esting LV systolic function:
global function—ejection
fraction
Indicate the ejection fraction category. Choose 1 of the following:
● Hyperdynamic: 70%
● Normal: 50%–70% (midpoint 60%)
● Mild dysfunction: 40%–49% (midpoint 45%)
● Moderate dysfunction: 30%–39% (midpoint 35%)
● Severe dysfunction: 30%
Note: If no diagnostic report is in the medical record, a value documented in the medical record is acceptable.
Diagnostic coronary
angiography
Indicate if the patient had diagnostic coronary angiography. This is defined as the passage of a catheter into the aortic root or
other great vessels for angiography of the native coronary arteries or bypass grafts supplying native coronary arteries. This
element would NOT include noninvasive CT angiography.
Diagnostic coronary
angiography date/time
Indicate the date and time the patient had diagnostic coronary angiography, defined as the passage of a catheter into the aortic
root or other great vessels.
Culprit artery This is the vessel considered to be responsible for the ACS. The investigator should use his or her judgment in choosing the
primary vessel. In cases in which this is difficult to determine (despite correlation of electrocardiographic changes and
angiographic data), the vessel supplying the largest territory of myocardium should be selected:
● LAD
● LCx
● RCA
● LM
● Graft
● Unknown
Note: “None” should be considered if there is no apparent coronary vessel lesion that could be responsible for evidence of
ischemia.
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therapy is an acceptable mode of reperfusion in cases where
Table 5. Continued
Element Name
ulprit artery TIMI flow TIMI grade flow in the culprit artery is defined
● Grade 0 (no perfusion): There is no antegrade
● Grade 1 (penetration without perfusion): The
opacify the entire coronary bed distal to t
● Grade 2 (partial perfusion): The contrast mat
obstruction. However, the rate of entry of
from the distal bed (or both) is perceptib
previously occluded vessel (e.g., the oppo
● Grade 3 (complete perfusion): Antegrade flow
bed from the involved bed and is as rapid
M stenosis percent The best estimate of the most severe percent
following:
● Percent stenosis of the LM coronary artery.
● If no stenosis, then enter 0%.
● If data are not available, indicate “not availab
Stenosis: Stenosis represents the percent diam
Percent stenosis at its maximal point is e
vessel proximal to the lesion. In instance
Note: If the patient only has a PCI (without a d
catheterization lab visit information, even
roximal LAD and first
diagonal branches
percent stenosis
Indicate the best estimate of the most severe
2.0 mm in diameter as determined by
● Percent stenosis of the proximal LAD and firs
● If no stenosis, then enter 0%.
● If data are not available, indicate “not availab
Stenosis: Stenosis represents the percent diam
Percent stenosis at its maximal point is e
vessel proximal to the lesion. In instance
Note: If the patient only has a PCI (without a d
catheterization lab visit information, even
id/distal LAD, D2, and D3
percent stenosis
Indicate the best estimate of the most severe
the first diagonal of 2.0 mm in diamete
the following:
● Percent stenosis of the mid/distal LAD, D2, a
● If no stenosis, then enter 0%.
● If data are not available, indicate “not availab
Stenosis: Stenosis represents the percent diam
Percent stenosis at its maximal point is e
vessel proximal to the lesion. In instance
If the patient only has a PCI (without a diagno
catheterization lab visit information, even
irc, OMs, LPDA, and LPL
branches percent stenosis
Indicate the best estimate of the most severe
2.0 mm in diameter as determined by
● Percent stenosis of the Circ, OMs, LPDA, and
● If no stenosis, then enter 0%.
● If data are not available, indicate “not availab
Stenosis: Stenosis represents the percent diam
Percent stenosis at its maximal point is e
vessel proximal to the lesion. In instance
If the patient only has a PCI (without a diagno
catheterization lab visit information, even
CA, PDA, RPL, and AM
branches percent stenosis
Indicate the best estimate of the most severe
as determined by angiography. This does
● Percent stenosis of the RCA, PDA, RPL, and A
● If no stenosis, then enter 0%.
● If data are not available, indicate “not availab
Stenosis: Stenosis represents the percent diam
Percent stenosis at its maximal point is e
vessel proximal to the lesion. In instance
If the patient only has a PCI (without a diagno
catheterization lab visit information, evenPCI is not available, detailed information is collected on type,dosage, and timing of thrombolysis. Data collection for other
medications that impact the function of the heart and the
Element Definition
ows:
beyond the point of occlusion.
st material passes beyond the area of obstruction but “hangs up” and fails to
struction for the duration of the cineangiographic filming sequence.
asses across the obstruction and opacifies the coronary bed distal to the
ast material into the vessel distal to the obstruction or its rate of clearance
er than its entry into or clearance from comparable areas not perfused by the
oronary artery or the coronary bed proximal to the obstruction).
the bed distal to the obstruction occurs as promptly as antegrade flow into the
earance from an uninvolved bed in the same vessel or the opposite artery.
is in the LM coronary artery. This does not include collaterals. Indicate the
eduction, from 0 to 100, associated with the identified vessel systems.
ted to be the amount of reduction in the diameter of the “normal” reference
re multiple lesions are present, enter the single highest percent stenosis noted.
stic catheterization at the same sitting), it is acceptable to use prior and recent
another institution.
nt stenosis in the proximal LAD and first diagonal coronary artery branches of
raphy. This does not include collateral circulation. Indicate the following:
onal branches.
eduction, from 0 to 100, associated with the identified vessel systems.
ted to be the amount of reduction in the diameter of the “normal” reference
re multiple lesions are present, enter the single highest percent stenosis noted.
stic catheterization at the same sitting), it is acceptable to use prior and recent
another institution.
nt stenosis in the mid/distal LAD and diagonal coronary artery branches after
etermined by angiography. This does not include collateral circulation. Indicate
.
eduction, from 0 to 100, associated with the identified vessel systems.
ted to be the amount of reduction in the diameter of the “normal” reference
re multiple lesions are present, enter the single highest percent stenosis noted.
theterization at the same sitting), it is acceptable to use prior and recent
another institution.
nt stenosis in the Circ, OMs, LPDA, and LPL coronary artery branches of
raphy. This does not include collaterals. Indicate the following:
ranches.
eduction, from 0 to 100, associated with the identified vessel systems.
ted to be the amount of reduction in the diameter of the “normal” reference
re multiple lesions are present, enter the single highest percent stenosis noted.
theterization at the same sitting), it is acceptable to use prior and recent
another institution.
nt stenosis in the RCA, PDA, RPL, and AM branches of 2.0 mm in diameter
clude collaterals. Indicate the following:
nches.
eduction, from 0 to 100, associated with the identified vessel systems.
ted to be the amount of reduction in the diameter of the “normal” reference
re multiple lesions are present, enter the single highest percent stenosis noted.
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Element Name Element Definition
amus percent stenosis Indicate the best estimate of the most severe percent stenosis in the ramus artery (if present) of 2.0 mm in diameter as
determined by angiography. This does not include collaterals. Indicate the following:
● Percent stenosis of the ramus.
● If no stenosis, then enter 0%.
● If data are not available, indicate “not available.”
Stenosis: Stenosis represents the percent diameter reduction, from 0 to 100, associated with the identified vessel systems.
Percent stenosis at its maximal point is estimated to be the amount of reduction in the diameter of the “normal” reference
vessel proximal to the lesion. In instances where multiple lesions are present, enter the single highest percent stenosis
noted.
If the patient only has a PCI (without a diagnostic catheterization at the same sitting), it is acceptable to use prior and recent
catheterization lab visit information, even if at another institution.
atheterization
contraindication
Indicate if catheterization was not performed. Contraindications may include patient refusal, advanced age, patient not a
candidate for revascularization, DNR order, active bleeding, and clinical contraindications/severe comorbidities.
eperfusion Therapy
eperfusion therapy:
reperfusion candidate
Indicate if the patient is a candidate for reperfusion therapy for treatment of STEMI. Reperfusion therapy includes thrombolysis
and primary PCI. Choose 1 of the following:
● Yes
● No
eperfusion therapy: type of
reperfusion
If the patient received reperfusion therapy, indicate the type of reperfusion. Choose all that apply:
● Primary PCI
● Thrombolytic therapy
CI
PCI Indicate if the patient underwent PCI, placement of an angioplasty guidewire, balloon, or other device (e.g., stent, atherectomy,
brachytherapy, or thrombectomy catheter) into a native coronary artery or CABG for the purpose of mechanical coronary
revascularization.
Catheterization lab arrival
date/time
Indicate the date and time the patient arrived at the catheterization lab where the PCI was being performed as documented in the
medical record.
First device activation
date/time
Indicate the date and time the first device was activated regardless of the type of device used. Use the earliest time from the
following:
● Time of first balloon inflation
● Time of first stent deployment
● Time of first treatment of lesion (thrombectomy/aspiration device, laser, rotational atherectomy)
● If the lesion cannot be crossed with a guidewire or device (and thus none of the above apply), use the time of guidewire
introduction.
Please note that this is a process measure about the timeliness of treatment. It is NOT a clinical outcomes measure based on
TIMI flow or clinical reperfusion. It does not matter whether the baseline angiogram showed TIMI 3 flow or if the final post-
PCI angiogram showed TIMI 0 flow. What is being measured is the time of the first mechanical treatment of the culprit
lesion, not the time when TIMI 3 flow was (or was not) restored.
PCI indication Indicate the primary reason PCI was performed or attempted. Choose 1 of the following:
● Immediate, primary PCI for STEMI
● Stable following successful reperfusion or completed infarction after STEMI
● Rescue PCI (after failed full-dose lytics for STEMI)
● PCI for NSTEMI
● Other
Nonsystem reason for
delay in PCI
Indicate if there is documentation of a reason for a delay in doing the first PCI after hospital arrival by a physician/advanced
practice nurse/physician assistant. System reasons for delay are NOT acceptable.
● Difficult vascular access
● Cardiac arrest and/or need for intubation before PCI
● Patient delay in providing consent for procedure
● Difficulty crossing the culprit lesion during PCI procedure
● Other
● None
Stent placed Indicate if a stent was placed in the affected coronary artery.
Stent type Indicate the type of stent if a stent was placed in the affected coronary artery.
Choose all that apply:
● Drug-eluting stent
● Bare metal stent
● Other stent
Number of stents placed Number of stents placed. The exact type of stent should be collected.
hrombolytics
Thrombolytics type If the patient received reperfusion therapy with thrombolytics, indicate the type of thrombolytics used. Choose 1 of the following:
● Alteplase
● Reteplase
● Streptokinase
● Tenecteplase
● Other
CO
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zine therapy, warfarin/new anticoagulants, angiotensin-
Table 5. Continued
Element Name
Thrombolytics dose If the patient received reperfusion therapy wit
following:
● Full dose
● Reduced dose
Thrombolytics start date/
time
If the patient received reperfusion therapy wit
infusion.
Note: If the facility receives a transfer patient
transferring facility.
Nonsystem reason for
delay of thrombolytics
Indicate if there is documentation of a nonsys
first facility arrival (including an ambulan
Note: A patient being transferred into a facility
ontraindications for reperfusion therapy
Contraindication to PCI Indicate why PCI was not performed as reperf
● Noncompressible vascular puncture(s)
● Active bleeding on arrival or within 24 h
● Quality-of-life decision
● Anatomy not suitable for primary PCI
● Spontaneous reperfusion (documented by ca
● Patient/family refusal
● DNR order in place at time of treatment dec
● Prior allergic reaction to IV contrast
● Facility is not a PCI center
● Other
Contraindication to
thrombolytics
Indicate why thrombolytics were not administ
● Known bleeding diathesis
● Recent bleeding within 4 wk
● Recent surgery/trauma
● Intracranial neoplasm, AV malformation, or a
● Severe uncontrolled hypertension
● Suspected aortic dissection
● Significant close head or facial trauma withi
● Active peptic ulcer
● Traumatic CPR that precludes thrombolytics
● Ischemic stroke within 3 mo except acute is
● Any prior intracranial hemorrhage
● Pregnancy
● Prior allergic reaction to thrombolytics
● DNR order in place at time of treatment dec
● Patient/family refusal
● Other
ther Invasive Therapeutic Interventions
CABG surgery Indicate if the patient underwent CABG surger
CABG surgery date/time Indicate the date and time the patient entered
operating room report.
IABP Indicate if IABP was used during this admissio
Circulatory support Indicate if circulatory support was provided du
● IABP
● Tandem Heart
● Impella
● ECMO
● LVAD
● BiVAD
● Other
Pulmonary artery catheter Indicate if a pulmonary artery (Swan Ganz) ca
Ventilator Indicate the need for intubation and respirato
taken off the ventilator.
ACS indicates acute coronary syndrome; AM, acute marginal; AV, arteriovenous; BiVAD, bive
resuscitation; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy d
branch 2; D3 diagonal branch 3; DNR, do not resuscitate; ECG, electrocardiogram; ECMO, extraco
IV, intravenous; LAD, left anterior descending; LBBB, left bundle-branch block; LCx, left circumfle
left ventricular assist device; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertr
marginal; PCI, percutaneous coronary intervention; PDA, posterior descending artery; RCA, righ
Thrombolysis in Myocardial Infarction; VF, ventricular fibrillation; and VT, ventricular tachycardiaconverting enzyme inhibitors, angiotensin receptor blockers,aldosterone, diuretics, statins, and other lipid-lowering medi-
cations, nonsteroidal anti-inflammatory drugs, insulin, oral
Element Definition
mbolytics, indicate the strength of dose of the thrombolytics. Choose 1 of the
mbolytics, indicate the time of either the first bolus or the beginning of the
ngoing infusion, record the time that the infusion was started at the
ason for delay in initiating thrombolytic therapy 30 min from the time of
pable of administering thrombolytic therapy).
t considered a nonsystem reason for delay.
therapy. Choose 1 of the following:
rization only)
s reperfusion therapy. Choose 1 of the following:
sm
ious 3 mo
c stroke within 3 h
ng this admission.
perating room suite or the first time surgery was documented on the
is admission and which type:
was used during this admission.
port on a ventilator. Include the date and time the patient was put on and
r assist device; CABG, coronary artery bypass graft; Circ, circumflex; CPR, cardiopulmonary
tor; CRT-P, cardiac resynchronization therapy pacemaker; CT, computed tomography; D2 diagonal
membrane oxygenation; IABP, intraortic balloon pump; ICD, implantable cardioverter-defibrillator;
left main; LPDA, left posterior descending artery; LPL left posterolateral; LV, left ventricle; LVAD,
R, magnetic resonance; NSTEMI, non-ST-segment elevation myocardial infarction; OM, obtuse
ary artery; RPL, right posterolateral; STEMI, ST-segment elevation myocardial infarction; TIMI,h thro
h thro
with o
tem re
ce ca
is no
usion
thete
ision
ered a
neury
n prev
chemi
ision
y duri
the o
n.
ring th
theter
ry sup
ntricula
efibrilla
rporeal
x; LM,
ophy; Mhypoglycemics, influenza, and pneumococcal immunizations.
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Element Name Element Definition
P IIb/IIIa blocker Indicate if a GP IIb/IIIa inhibitor was administered during the hospital stay. If yes, indicate which of the following:
● Eptifibatide
● Tirofiban
● Abciximab
P IIb/IIIa blocker dosage Indicate the GP IIb/IIIa blocker dose given.
P IIb/IIIa inhibitor
administered start
date/time
Indicate the date and time a GP IIb/IIIa inhibitor infusion was initiated during the hospital stay.
P IIb/IIIa inhibitor
administered stop
date/time
Indicate the date and time the GP IIb/IIIa inhibitor infusion was permanently discontinued during the hospital stay.
P IIb/IIIa inhibitor
contraindicated
Indicate if a GP IIb/IIIa inhibitor was contraindicated during the hospital stay.
nticoagulant (parenteral) Indicate if an anticoagulant was administered during the hospital stay. If yes, indicate which of the following:
● IV unfractionated
● Low molecular weight
● Bivalirudin
● Fondaparinux
● Other
nticoagulant dose Indicate the anticoagulant dose given.
nticoagulant start
date/time
Indicate the date and time an anticoagulant infusion was initiated during the hospital stay.
nticoagulant stop
date/time
Indicate the date and time an anticoagulant infusion was permanently discontinued during the hospital stay.
nticoagulant
contraindicated
Indicate if an anticoagulant agent was contraindicated during the hospital stay.
V nitrate Nitroglycerin was administered intravenously.
ral or topical nitrates Oral or topical nitroglycerin was administered. Commonly prescribed agents include isosorbide dinitrate, isosorbide mononitrate,
transdermal infusion system, or nitroglycerin paste. Sublingual nitroglycerin or nitroglycerin spray used on an as-needed basis
only should not be noted in this category.
V beta blocker Indicate if IV beta blockers were administered. Some forms of IV beta blockers include atenolol, metoprolol, propranolol, timolol,
esmolol, and labetalol.
eta blocker before
admission
Indicate if the patient has been taking a beta blocker routinely at home before this hospitalization. If yes, indicate which type.
eta blocker in first 24 h Indicate if the beta blocker was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring
facility or EMS). If yes, indicate which type. Medications taken at home before hospital arrival and therefore not readministered
until the next day of the hospitalization should be noted.
eta-blocker
contraindications
Indicate if a beta blocker was not administered during the first 24 h of care because of a contraindication. A contraindication that
is not documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
eta blocker (discharge) Indicate if a beta blocker was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
eta blocker (discharge)
contraindicated
Indicate if a beta blocker was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is
not documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
alcium channel blocker Indicate if calcium channel blockers were administered. If yes, indicate which type. Some generic forms of calcium channel
blockers are verapamil, nifedipine, diltiazem, nicardipine, nimodipine, nisoldipine, felodipine, and amlodipine.
anolazine before
admission
Indicate if the patient has been taking ranolazine routinely at home before this hospitalization.
anolazine in first 24 h Indicate if ranolazine was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
anolazine (discharge) Indicate if ranolazine was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
spirin before admission Indicate if the patient has been taking aspirin routinely at home before this hospitalization:
● 81 mg
● 162 mg
● 325 mg
● 325 mg
● Other
spirin in first 24 h Indicate if aspirin was administered in the first 24 h before or after hospital arrival, regardless of location of care (e.g., transferring
facility or EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
spirin dose Indicate dose of aspirin given for the first 24 h.
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Element Name Element Definition
spirin contraindications Indicate if aspirin was not administered during the first 24 h of care because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
spirin (discharge) Indicate if aspirin was continued or prescribed at hospital discharge.
spirin (discharge) dose Indicate the daily dose prescribed.
● 81 mg
● 162 mg
● 325 mg
● 325 mg
● Other
spirin (discharge)
contraindicated
Indicate if aspirin was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
ther oral anticoagulants
before admission
Indicate if the patient has been taking other oral anticoagulants (oral direct antithrombin inhibitor, e.g., dabigatran or oral direct
factor Xa inhibitor, e.g., rivaroxaban, apixaban) routinely at home before this hospitalization.
ther oral anticoagulant Indicate if other oral anticoagulant was administered in the first 24 h of care provided, regardless of location of care (e.g.,
transferring facility or EMS). If yes, indicate which type. Medications taken at home before hospital arrival and therefore not
readministered until the next day of the hospitalization should be noted.
ther oral anticoagulant
(discharge)
Indicate if other oral anticoagulant was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
arfarin before admission Indicate if the patient has been taking warfarin routinely at home before this hospitalization.
arfarin Indicate if warfarin was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). If yes, indicate which type. Medications taken at home before hospital arrival and therefore not readministered until the
next day of the hospitalization should be noted.
arfarin (discharge) Indicate if warfarin was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
arfarin or other oral
anticoagulant (discharge
contraindication)
Indicate if warfarin was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
lopidogrel before
admission
Indicate if the patient has been taking clopidogrel routinely at home before this hospitalization.
lopidogrel in first 24 h Indicate if clopidogrel was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
lopidogrel loading dose Indicate the amount of the initial dose:
● 75 mg
● 150 mg
● 300 mg
● 600 mg
● Other
lopidogrel start date/time Indicate the date and time the initial dose was given.
lopidogrel contraindicated Indicate if clopidogrel was not administered during the first 24 h of care because of a contraindication. A contraindication that is
not documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
lopidogrel (discharge) Indicate if clopidogrel was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
lopidogrel (discharge)
contraindicated
Indicate if clopidogrel was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
rasugrel before admission Indicate if the patient has been taking prasugrel routinely at home before this hospitalization.
rasugrel in first 24 h Indicate if prasugrel was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
rasugrel start date/time Indicate the date and time the initial dose was given.
rasugrel contraindicated Indicate if prasugrel was not administered during the first 24 h of care because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
rasugrel (discharge) Indicate if prasugrel was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed. DO NOT record
discharge medication if patient was transferred to another acute care facility from your hospital.
rasugrel (discharge)
contraindicated
Indicate if prasugrel was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
icagrelor before admission Indicate if the patient has been taking ticagrelor routinely at home before this hospitalization.
icagrelor in first 24 h Indicate if ticagrelor was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
icagrelor start date/time Indicate the date and time the initial dose was given.
icagrelor contraindicated Indicate if ticagrelor was not administered during the first 24 h of care because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
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Element Name Element Definition
icagrelor (discharge) Indicate if ticagrelor was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed. DO NOT record
discharge medication if the patient was transferred to another acute care facility from your hospital.
icagrelor (discharge)
contraindicated
Indicate if ticagrelor was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
ther oral antiplatelet
medications before
admission
Indicate if the patient has been taking other oral antiplatelet medications routinely at home before this hospitalization. These may
include ticlopidine, dipyridamole, or cilostazol.
ther oral antiplatelet
medications in first 24 h
Indicate if other oral antiplatelets were administered in the first 24 h of care provided, regardless of location of care (e.g.,
transferring facility or EMS). Indicate which type and the dose administered. Medications taken at home before hospital arrival
and therefore not readministered until the next day of the hospitalization should be noted.
ther oral antiplatelet
medications (discharge)
Indicate if other oral antiplatelet medications were continued or prescribed at hospital discharge. Indicate which type and the dose
prescribed. DO NOT record discharge medication if the patient was transferred to another acute care facility from your hospital.
ther oral antiplatelet
medications (discharge)
contraindicated
Indicate if other oral antiplatelet medications were discontinued or not prescribed at discharge because of a contraindication. A
contraindication that is not documented explicitly by the healthcare provider but is evidenced clearly within the medical record
should be noted.
CE inhibitor before
admission
Indicate if the patient has been taking an ACE inhibitor routinely at home before this hospitalization.
CE inhibitor in first 24 h Indicate if an ACE inhibitor was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring
facility or EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
CE inhibitor
contraindicated
Indicate if an ACE inhibitor was not administered during the first 24 h of care because of a contraindication. A contraindication that
is not documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
CE inhibitor (discharge) Indicate if an ACE inhibitor was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed. DO NOT
record discharge medication if the patient was transferred to another acute care facility from your hospital.
CE inhibitor (discharge)
contraindicated
Indicate if an ACE inhibitor was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is
not documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
RB before admission Indicate if the patient has been taking an ARB routinely at home before this hospitalization.
RB in first 24 h Indicate if an ARB was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Medications taken at home before hospital arrival and therefore not readministered until the next day of the
hospitalization should be noted.
RB contraindicated Indicate if an ARB was not administered during the first 24 h of care because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
RB (discharge) Indicate if an ARB was continued or prescribed at hospital discharge. Indicate which type and the dose prescribed.
RB (discharge)
contraindicated
Indicate if an ARB was discontinued or not prescribed at discharge because of a contraindication. A contraindication that is not
documented explicitly by the healthcare provider but is evidenced clearly within the medical record should be noted.
iuretic Indicate if a diuretic was continued or prescribed at hospital discharge. Aldosterone inhibitor is listed separately.
ldosterone blocking agent
(home)
Indicate if the patient has been taking an aldosterone blocking agent routinely at home before this hospitalization.
ldosterone blocking agent
in first 24 h
Indicate if an aldosterone blocking agent was administered in the first 24 h of care provided, regardless of location of care (e.g.,
transferring facility or EMS). Indicate which type and the dose administered. Medications taken at home before hospital arrival
and therefore not readministered until the next day of the hospitalization should be noted.
ldosterone blocking agent
dose
Indicate the aldosterone blocking agent dose given.
ldosterone blocking agent
(24 h) contraindicated
Indicate if an aldosterone blocking agent was not administered during the first 24 h of care because of a contraindication. A
contraindication that is not documented explicitly by the healthcare provider but is evidenced clearly within the medical record
should be noted.
ldosterone blocking agent
(discharge)
Indicate if an aldosterone blocking agent was continued or prescribed at hospital discharge. Indicate which type and the dose
prescribed. DO NOT record discharge medication if the patient was transferred to another acute care facility from your hospital.
ldosterone blocking agent
(discharge)
contraindicated
Indicate if an aldosterone blocking agent was discontinued or not prescribed at discharge because of a contraindication. A
contraindication that is not documented explicitly by the healthcare provider but is evidenced clearly within the medical record
should be noted.
tatin before admission Indicate if the patient has been taking a statin routinely at home before this hospitalization.
tatin in first 24 h Indicate if a statin was administered in the first 24 h of care provided, regardless of location of care (e.g., transferring facility or
EMS). Indicate which type of statin was administered. Medications taken at home before hospital arrival and therefore not
readministered until the next day of the hospitalization should be noted.
tatin dose Indicate the following:
● Specific statin agent
● Statin dose given
SS
S
O
O
O
O
A
A
F
N
N
I
O
S
I
P
tidyl p
1014 Cannon et al. JACC Vol. 61, No. 9, 2013
2013 ACCF/AHA Data Standards March 5, 2013:992–10253.7. Outcomes Data Elements
Clinical trials on STEMI, NSTEMI, and UA patients and
research published from ACS registries have established
well-defined data elements that reflect clinically relevant
outcomes in these patient groups. Outcome data elements
(Table 7) that have been selected by the writing committee
include death during hospitalization (with timing and pri-
mary cause being either cardiovascular or noncardiovascu-
lar), occurrence of reinfarction (using the universal defi-
nition of MI), heart failure, cardiogenic shock, stroke,
TIMI major or minor bleeding, GUSTO bleeding, loca-
tion of the bleeding event, surgical intervention required
for bleeding, transfusion required, amount of blood
given, thrombocytopenia, cardiac rupture, atrial fibrilla-
tion, ventricular arrhythmia, and atrioventricular block.
Table 6. Continued
Element Name
tatin contraindicated Indicate if statin was not administered during t
documented explicitly by the healthcare pro
tatin (discharge) Indicate if a statin was continued or prescribed
discharge medication if the patient was tran
tatin (discharge)
contraindicated
Indicate if statin medication was discontinued
documented explicitly by the healthcare pro
ther lipid-lowering agent
(home)
Indicate if the patient has been taking another
ther lipid-lowering agent
(discharge)
Indicate if another lipid-lowering agent was continu
ther lipid-lowering agent
(discharge)
contraindicated
Indicate if another lipid-lowering agent was dis
contraindication that is not documented exp
should be noted.
mega-3 fatty acid
(discharge)
Indicate if a preparation of omega-3 fatty acid
ntiarrhythmic (discharge) Indicate if an antiarrhythmic was administered
ntidepressants Indicate if the patient has been prescribed an
emale hormone
replacement therapy
Indicate if female hormone replacement thera
icotine replacement and/
or suppression therapy
Indicate if nicotine replacement and/or suppre
SAIDs Indicate if the patient has been prescribed an
● Nonselective
● Cox-2 selective
nsulin Indicate if the patient has been prescribed insu
ral hypoglycemic agent Indicate if the patient has been prescribed an
● Sulfonylureas (e.g., tolbutamide, glipizide)
● Biguanides (e.g., metformin, buformin)
● Meglitinides (e.g., repaglinide, nateglinide)
● Thiazolidinediones (e.g., rosiglitazone, pioglita
● Peptide analogs
● DPP-4 inhibitors (e.g., vildagliptin, sitagliptin)
● Alpha-glucosidase inhibitors (e.g., miglitol, ac
● Experimental agents
ubcutaneous
hypoglycemic agent
Indicate if the patient has been prescribed a su
nfluenza immunization Indicate if the patient has received immunizati
neumococcal
immunization
Indicate if the patient has been immunized for
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DPP, dipep
nonsteroidal anti-inflammatory drug.Data elements have been included that capture dischargestatus, discharge destination, and The Joint Commission
discharge core measures reflecting optimal patient care.
The availability of long-term outcome data on patients
with ACS is essential in determining the efficacy of
therapies. Data elements have been selected for patient
follow-up after discharge to reflect important aspects of
patient status. These include anginal status, need for cardiac
catheterization, reinfarction, revascularization (either PCI or
coronary artery bypass graft), readmission to the hospital and
reason for readmission, important laboratory tests about risk
factors (low-density lipoprotein, high-density lipoprotein, he-
moglobin A1c, C-reactive protein), occurrence of heart failure
and New York Heart Association class, medication use, and
death (timing and cause). The timing of collection of outcomes
can be determined by the specific registry or trial; for example,
Element Definition
t 24 h of care because of a contraindication. A contraindication that is not
ut is evidenced clearly within the medical record should be noted.
spital discharge. Indicate which type and the dose prescribed. DO NOT record
d to another acute care facility from your hospital.
prescribed because of a contraindication. A contraindication that is not
ut is evidenced clearly within the medical record should be noted.
owering agent routinely at home before this hospitalization.
rescribed at hospital discharge. Indicate which type and the dose prescribed.
ued or not prescribed at discharge because of a contraindication. A
by the healthcare provider but is evidenced clearly within the medical record
ment/medication was taken at discharge.
pressant.
administered.
agents were administered (e.g., bupropion, varenicline).
. Indicate the type:
poglycemic agent for treatment of diabetes. Specify the agent:
)
neous hypoglycemic agent for treatment of diabetes.
influenza or received one in the past 12 mo.
ococcal pneumonia or received one in the past 12 mo.
eptidase; EMS, emergency medical services; GP, glycoprotein; IV, intravenous; and NSAID,he firs
vider b
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Element Name Element Definition
utcomes
eath The patient died during this hospitalization.
ate and time of death Indicate the patient’s date and time of death.
cute MI The term acute MI should be used when there is evidence of myocardial necrosis in a clinical setting consistent with
myocardial ischemia. Under these conditions, any one of the following criteria meets the diagnosis for MI:
● Detection of the rise and/or fall of cardiac biomarkers (preferably cTn) with at least 1 value above the 99th percentile and
with at least 1 of the following
- Symptoms of ischemia
- New or presumed new significant ST-T changes or new LBBB
- Development of pathological Q waves on the ECG
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
- Identification of an intracoronary thrombus by angiography or autopsy
● Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic
changes or new LBBB, but death occurred before cardiac biomarkers were obtained or before cardiac biomarker values
would be increased.
● PCI-related MI is arbitrarily defined by elevation of cTn values (5 times the 99th percentile URL) in patients with normal
baseline values (99th percentile URL) or a rise in cTn values 20% if baseline values are elevated and stable or falling;
in addition, either symptoms suggestive of myocardial ischemia or new ischemic electrocardiographic changes or
angiographic findings consistent with a procedural complication or imaging demonstration of new loss of viable
myocardium or new regional wall motion abnormality
● Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial
ischemia and with a rise and/or fall of cardiac biomarker values with at least 1 value 99th percentile URL.
● CABG-related MI is arbitrarily defined by elevation of cardiac biomarker values (10 times the 99th percentile URL) in
patients with normal baseline cTn values (99th percentile URL) plus either new pathological Q waves or new
LBBB, or angiographically documented new graft or new native coronary artery occlusion, or imaging evidence of
new loss of viable myocardium.
● The 99th percentile is observed after the procedure in conjunction with symptoms suggestive of myocardial ischemia or
new ischemic electrocardiographic changes or angiographic findings consistent with a procedural complication or
imaging demonstration of new loss of viable myocardium or in patients with a preprocedure elevated biomarker
that is stable or falling, a rise of biomarker values 20% in conjunction with the PCI-related criteria stated above.
Recurrent MI Reinfarction occurs when there are clinical signs and symptoms of ischemia that are distinct from the presenting ischemic
event and meeting at least 1 of the following criteria:
1. Spontaneous (before or without revascularization, 48 h after PCI, and/or after CABG)
A. New, significant Q waves in at least 2 contiguous leads of an ECG that were not present with the presenting ischemic
event
B. Patients whose most recent cardiac markers drawn before reinfarction, which were normal, require an increase in
CK-MB or troponin above the 99th percentile ULN, which is at least 20% above the most recent value.
2. Within 48 h after PCI:
A. Patients with normal biomarker values (preprocedure) who then develop an increase in biomarker values 5 times the
99th percentile URL or if the baseline values are elevated and are stable or falling, a rise of cTn values 20%. In
addition, symptoms suggestive of myocardial ischemia or new ischemic electrocardiographic changes or
angiographic findings consistent with a procedural complication or imaging demonstration of new loss of viable
myocardium are required.
Note: Some patients presenting with ACS will not have biomarker elevations before the PCI. Elevated biomarkers after PCI
in these cases do not necessarily mean a reinfarction occurred.
B. Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial
ischemia and with a rise and/or fall of cardiac biomarker values with at least 1 value above the 99th percentile
URL
C. For patients with elevated baseline (preprocedure) cardiac biomarkers, there are 2 possible scenarios. In these
scenarios, electrocardiographic changes or symptoms are not required to qualify.
i. Patients with cardiac markers above the ULN (preprocedure) assumed to be in the midst of an acute MI
ii. Patients with elevated biomarkers with a characteristic rise and fall in biomarker levels preprocedure most likely have
completed their presenting infarct. Further rises in cardiac markers must be 20% above the most recent value to
be coded as reinfarction.
D. Patients with new, significant Q waves in at least 2 contiguous leads of an ECG that were not present with the
presenting ischemic event
3. Within 48 h after CABG: A CABG-related MI is defined by elevation of cardiac biomarker values 10 times the 99th
percentile URL in patients with normal baseline cTn values (99th percentile URL) plus either new pathological
Q waves or new LBBB or angiographically documented new graft or new native coronary artery occlusion or
imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Note: Patients with cardiac biomarkers above the ULN before CABG require the increase in biomarkers to be 20% above
the most recent value associated with symptoms/signs of myocardial ischemia.
Reinfarction date Indicate the date when the clinical signs and symptoms of the reinfarction first occurred.
Recurrent rest angina with
electrocardiographic
changes
Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) with associated electrocardiographic changes
Recurrent rest angina without
electrocardiographic
changes
Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) without associated electrocardiographic
changes
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Unstable angina requiring
hospitalization
Unstable angina requiring hospitalization is defined as:
1. Ischemic discomfort (angina or symptoms thought to be equivalent) 10 min in duration occurring
● at rest, or
● in an accelerating pattern with frequent episodes associated with progressively decreased exercise capacity
2. Prompting an unscheduled hospitalization within 24 h of the most recent symptoms. Hospitalization is defined as an
admission to an inpatient unit or a visit to an emergency department that results in at least a 24 h stay (or a
change in calendar date if the hospital admission or discharge times are not available)
3. At least one of the following:
a. New or worsening ST or T wave changes on resting ECG (in the absence of confounders, such as LBBB or LVH)
● Transient ST elevation (duration 20 min)
New ST elevation at the J point in 2 contiguous leads with the cut-points: 0.1 mV in all leads other than leads V2-V3
where the following cut-points apply: 0.2 mV in men 40 y (0.25 mV in men 40 y) or 0.14 mV in women
● ST depression and T-wave changes
New horizontal or down-sloping ST depression 0.05 mV in two contiguous leads and/or new T inversion 0.3 mV in
2 contiguous leads with prominent R wave or R/S ratio 1.
b. Definite evidence of inducible myocardial ischemia as demonstrated by:
● an early positive exercise stress test, defined as ST elevation or 2 mm ST depression prior to 5 METS, or
● stress echocardiography (reversible wall motion abnormality), or
● myocardial scintigraphy (reversible perfusion defect), or
● MRI (myocardial perfusion deficit under pharmacologic stress) and believed to be responsible for the myocardial
ischemic symptoms/signs.
c. Angiographic evidence of new or worse 70% lesion and/or thrombus in an epicardial coronary artery that is believed
to be responsible for the myocardial ischemic symptoms/signs.
d. Need for coronary revascularization procedure (PCI or CABG) for the presumed culprit lesion(s). This criterion would be
fulfilled if revascularization was undertaken during the unscheduled hospitalization, or subsequent transfer to
another institution without interceding home discharge.
4. Negative cardiac biomarkers.
Heart failure Indicate if there is physician documentation or report of either new-onset or acute reoccurrence of heart failure.
Heart failure is defined as physician documentation or report of any of the following clinical symptoms of heart failure
described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention;
or the description of rales, jugular venous distention, or pulmonary edema on physical exam. A low ejection
fraction without clinical presentation does not qualify as heart failure.
*Note: Killip class 2 is defined as rales over 50% of the lung fields or the presence of an S3. Killip class 3 is defined as
rales over 50% of the lung fields. Either class would qualify as a “yes.”
Heart failure date Indicate the date of the acute reoccurrence of heart failure.
Cardiogenic shock Indicate if the patient developed cardiogenic shock in your facility. Cardiogenic shock is defined as a sustained (30 min)
episode of systolic blood pressure 90 mm Hg and/or cardiac index 2.2 L/min per square meter determined to
be secondary to cardiac dysfunction and/or the requirement for parenteral inotropic or vasopressor agents or
mechanical support (e.g., IABP, extracorporeal circulation, VADs) to maintain blood pressure and cardiac index
above those specified levels.
Note: Transient episodes of hypotension reversed with IV fluid or atropine do not constitute cardiogenic shock. The
hemodynamic compromise (with or without extraordinary supportive therapy) must persist for at least 30 min.
Cardiogenic shock date Indicate the date when a diagnosis for cardiogenic shock was made.
Stroke Indicate whether the patient has a history of stroke, which is defined as an acute episode of neurological dysfunction caused
by focal or global brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.
If present, record stroke type:
● Ischemic stroke
● Intracerebral hemorrhage
● Subarachnoid hemorrhage
● Unknown type
If ischemic, list the most likely etiologies:
● Large artery atherosclerosis of the extracranial vessels (e.g., carotid)
● Large artery atherosclerosis of the intracranial vessels (e.g., middle cerebral artery stenosis)
● Cardioembolism
● Small-vessel occlusion (lacunar)
● Ischemic stroke of other determined etiology (e.g., arterial dissection)
● Ischemic stroke of undetermined etiology
Stroke date Indicate the date of onset of stroke symptoms.
Type of stroke Indicate if the patient experienced a hemorrhagic or ischemic stroke with documentation on imaging (e.g., CT scan or MRI
of hemorrhage in the cerebral parenchyma or a subdural or subarachnoid hemorrhage). Evidence of hemorrhagic
stroke obtained from lumbar puncture, neurosurgery, or autopsy can also confirm the diagnosis.
Note: If stroke occurs during sleep, last awake time may be used.
Bleeding (TIMI major, TIMI minor,
or none)
An episode of bleeding is defined by the TIMI criteria as
● Major: overt clinical bleeding (or documented intracranial or retroperitoneal hemorrhage) associated with a drop in
hemoglobin of 5 g/dL (0.5 g/L) or in hematocrit of 15% (absolute)
Note: A patient who experiences an intracranial hemorrhage should be considered to have a major hemorrhage.
● Minor: overt clinical bleeding associated with a fall in hemoglobin of 3 to5 g/dL or in hematocrit of 9% to15% (absolute)
● None: no bleeding event that meets the major or minor definition
Note: In calculating the fall in hemoglobin or hematocrit, a transfusion of whole blood or packed RBCs is counted as 1 g/dL
hemoglobin or 3% absolute in hematocrit. This would be in addition to the actual fall in hemoglobin or hematocrit.
GUSTO bleeding classification (42) Indicate the GUSTO bleeding classification:
● Severe: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
● Moderate: bleeding that requires blood transfusion but does not result in hemodynamic compromise
● Mild: bleeding that does not meet the criteria for either severe or moderate bleeding
LV
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“Standardized Definitions for Cardiovascular and Stroke End
Point Events in Cardiovascular Trials” (41) from the FDA,
which is currently in development. It should also be noted that
the writing committee believes that further research is needed
Table 7. Continued
Element Name
Bleeding event Indicate if there was a bleeding event ob
drop of 10% and/or a hemog
ocation of bleeding Indicate the location thought to be respo
● Access site
● Retroperitoneal
● GI
● GU
● Other
Bleeding event date Indicate the date of the suspected bleed
Surgical or procedural
intervention
Indicate if the suspected bleeding event
protamine (heparin reversal a
Prolonged pressure does not q
diagnosis of pseudoaneurysm
Transfusion Indicate if there was a nonautologous tra
Units of blood given Indicate the units of blood given.
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● Deadfrom large observational databases to identify the actual trendsin duration of UA; however, the timing criteria for UA in
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the FDA’s Standardized Definitions for End Point
Events in Cardiovascular Trials definition. Future itera-
tions of the ACCF/AHA ACS/CAD data standards data
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Element Name Element Definition
rimary cause of death* Indicate the primary cause of death:
● Cardiovascular death:
- Acute MI
- Sudden cardiac death
- Death due to heart failure
- Death due to stroke
- Death due to cardiovascular procedures
- Death due to cardiovascular hemorrhage
- Death due to other cardiovascular causes
● Noncardiovascular death: defined as any death with a specific cause that is not thought to be cardiovascular in nature:
- Pulmonary
- Renal
- GI
- Hepatobiliary
- Pancreatic
- Infection (includes sepsis)
- Inflammatory (e.g., SIRS/immune [including autoimmune])
- Hemorrhage that is neither cardiovascular bleeding nor a stroke
- Noncardiovascular procedure or surgery
- Trauma
- Suicide
- Prescription drug reaction or overdose
- Nonprescription drug reaction or overdose
- Neurological (noncardiovascular)
- Malignancy
- Other noncardiovascular cause of death
● Undetermined cause of death: refers to death not attributable to either cardiovascular or noncardiovascular cause
Acute care transfer Indicate if the patient was transferred to another acute-care center (hospital) for further management.
Date/time of transfer Indicate the date and time the patient was transferred to another acute-care center (hospital) for further management.
Days in ICU Total number of days the patient spent in an intensive care bed at the index hospital only, either consecutively or
intermittently. To count days:
● Find the ICU/CCU admit date/time and the date/time patient was transferred to another unit (telemetry or
unmonitored bed)
● For every 24-h period, count 1 d
● For any partial day remaining, round up if 12 h and round down if 12 h
In the case of an in-hospital infarct in which the patient is already in an ICU bed, record the number of days spent in ICU/CCU
after the diagnosis of MI was made.
inal diagnosis of the
admission event
● STEMI is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis (e.g., positive cTn or CK-MB)
and new (or presumably new if no prior ECG is available) ST-segment elevation or LBBB on the admission ECG.
(For a complete definition, please see “MI” in the “Outcomes” section.)
● NSTEMI is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis (e.g., positive cTn or CK-MB)
without new ST-segment elevation. (For a complete definition, please see “MI” in the “Outcomes” section.)
● BBB/uncertain type: For a complete definition, please see “MI” in the “Outcomes” section.
● UA is defined as angina pectoris (or equivalent type of ischemic discomfort) with any 1 of the 3 following features:
1. Angina occurring at rest and prolonged, usually 10 min
2. New-onset angina of at least CCS classification III severity
3. Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at least CCS class III
The patient must also not have any biochemical evidence of necrosis.
Definite/probable UA: Patients with clinical history consistent with the diagnosis of UA as described above, in whom
ischemia has been confirmed by the presence of ST changes on the initial ECG or in association with recurrent rest
pain, by a positive stress test, negative cardiac biomarkers, and no evidence of acute MI.
Possible UA is present when an acute ischemic process has not been excluded as a possible cause of the presenting
symptoms or the clinical history is consistent with UA, but no diagnostic test (noted above) was performed to
confirm the diagnosis.
● Stable CAD: The patient has a clinical diagnosis or prior history of CAD, but after evaluation in the hospital, the episode of
discomfort was not thought to have represented UA.
● Noncardiac chest pain: Pain in the chest, neck, arms, or abdomen (or other clinical manifestation) not clearly exertional or
not otherwise consistent with pain or discomfort of myocardial ischemic origin.
Examples:
1. If a patient was admitted with rest pain but had negative cardiac markers and then on day 3 developed recurrent pain,
and if it was determined that an MI had occurred, the event prompting admission should be coded as “unstable
angina” here. The MI on day 3 should be recorded in the “Outcomes” section as a postadmission MI.
2. If a patient was admitted with rest pain and the initial cardiac markers were negative but the enzymes drawn over the
subsequent 24 h became positive, this is most consistent with an NSTEMI as the admission event.
Comfort measures only Indicate if there was physician/nurse practitioner/physician assistant documentation that the patient was receiving comfort
measures only.
● Comfort measures only are commonly referred to as “palliative care” in the medical community and “comfort care” by the
general public. Palliative care includes attention to the psychological and spiritual needs of the patient and
support for the dying patient and the patient’s family. Usual interventions are not received because a medical
decision was made to limit care to comfort measures only.
● Comfort measures only are not equivalent to a DNR order, living will, no code, or no heroic measure.
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Element Name Element Definition
rimary inpatient service Indicate the specialty of the attending physician who primarily cared for the patient according to the most frequent and
consistent notations in the medical record.
Choose 1 of the following:
● Cardiology
● Internal medicine
● Family practice
● Hospital medicine (primary professional focus on general medical care of hospitalized patients)
● Other
Clinical trial Indicate if the patient signed an informed consent to participate in a clinical trial during his or her hospitalization, even if the
investigational medication, device, or procedure was never initiated.
Smoking cessation
counseling
Indicate if there was documentation in the medical record that smoking cessation advice or counseling was given during this
hospital stay.
Weight management
counseling
Advice is given or counseling conducted by a physician or nurse for patients who are 120% of ideal weight for height.
Particular emphasis on weight loss may be given for patients with hypertension, elevated triglycerides, or elevated
glucose levels.
Diet counseling Advice is given or a discussion conducted by a physician, nurse, or registered dietitian encouraging diet counseling. This can
include consumption of low-cholesterol foods; moderate restriction of sodium intake; emphasis on consumption of
fruits, vegetables, and low-fat dairy products; and increased consumption of omega-3 fatty acids.
Exercise counseling Indicate if advice was given or discussion conducted by a physician, nurse, or exercise specialist or nurse encouraging
patients to engage in a minimum of 30–60 min of physical activity daily or at least 3–4 times weekly.
Cardiac rehabilitation Indicate if advice was given or discussion conducted with the patient (by physician, nurse, or other personnel) about the
importance of joining a cardiac rehabilitation program or an appointment made.
Follow-up
Readmission Readmission to a hospital
Readmission date Date the patient was readmitted
Readmission reason Reasons for admission (include all that apply):
● MI (documented)
● UA
● Angina (without MI)
● PCI
● CABG
● CHF (without MI)
● Arrhythmia or conduction disturbance (without MI)
● Sudden cardiac arrest
● Chest pain ultimately found to be noncardiac in nature
● Stroke/other cardiovascular problem
● Noncardiovascular problem
BNP or NT pro-BNP Indicate the results of BNP or first NT pro-BNP. If done, enter the numerical value and specify which assay type was done.
LDL Indicate the value of LDL cholesterol. If the value is reported using a “” symbol (e.g., “300”), record the number only
(e.g., “300”).
HDL Indicate the value of HDL cholesterol. If the value is reported using a “” symbol (e.g., “300”), record the number only
(e.g., “300”).
Hemoglobin A1c Indicate value and date performed.
MI Documented evidence of an MI. For a complete definition, please see “MI” in the “Outcomes” section.
Cardiac catheterization Cardiac catheterization (with or without revascularization) procedure performed since the previous visit/contact
PCI PCI performed since the previous visit/contact
CABG CABG performed since the previous visit/contact
Angina status CCS classes of angina:
● Class 0: none
● Class I: ordinary physical activity, such as walking or climbing stairs, does not cause angina. Angina occurs with strenuous,
rapid, or prolonged exertion at work or recreation.
● Class II: slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or
climbing stairs after meals, or in cold, in wind, or under emotional stress, or only during the few hours after
awakening. Angina occurs on walking 2 blocks on the level and climbing 1 flight of ordinary stairs at a normal
pace and in normal conditions.
● Class III: marked limitation of ordinary physical activity. Angina occurs on walking 1 to 2 blocks on the level and climbing 1
flight of stairs in normal conditions and at a normal pace.
● Class IV: inability to perform any physical activity without discomfort—anginal symptoms may be present at rest.
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YHA functional class If heart failure is present, indicate NYHA
Choose 1 of the following:
● Class I: patients with cardiac disease b
cause undue fatigue, palpitati
● Class II: patients with cardiac disease r
Ordinary physical activity resu
● Class III: patients with cardiac disease
than ordinary activity causes f
● Class IV: patients with cardiac disease
are present even at rest or minimal e
Death The patient has died since the previous v
Date of death Indicate the date of death.
Primary cause of death Indicate the primary cause of death:
● Cardiovascular death:
- Acute MI
- Sudden cardiac death
- Death due to heart failure
- Death due to stroke
- Death due to cardiovascular procedu
- Death due to cardiovascular hemorrh
- Death due to other cardiovascular ca
● Noncardiovascular death is defined as
- Pulmonary
- Renal
- GI
- Hepatobiliary
- Pancreatic
- Infection (includes sepsis)
- Inflammatory (e.g., SIRS/immune [in
- Hemorrhage that is neither cardiovas
- Noncardiovascular procedure or surg
- Trauma
- Suicide
- Prescription drug reaction or overdos
- Nonprescription drug reaction or over
- Neurological (noncardiovascular)
- Malignancy
- Other noncardiovascular cause of dea
● Undetermined cause of death: refers to
Medication use ● Acetylsalicylic acid/antiplatelet: aspirin
● ACE inhibitors: Some common generic
● Beta blocker: Some forms of IV beta bl
generic forms of oral beta blo
bucindolol, bisoprolol, labetalo
● Lipid lowering: Types of agents include
(cholestyramine). Frequently p
atorvastatin, simvastatin, fluva
and aldosterone antagonists.
A complete listing of cardiac medication
ARB indicates angiotensin receptor blocker; ACE, angiotensin-converting enzyme; ACS, acute cor
coronary artery bypass graft; CAD, coronary artery disease; CAH, critical access hospital; CCS, Ca
kinase MB isoenzyme; CT, computed tomography; cTn, cardiac troponin; DNR, do not resus
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HDL, high-dens
IRF, inpatient rehabilitation facility; IV, intravenous; LBBB, left bundle branch block; LDL, low-d
imaging; NSTEMI, non-ST-segment elevation myocardial infarction; NT-proBNP, N-terminal proh
intervention; RBCs, red blood cells; SIRS, systemic inflammatory response syndrome; SNF, skille
Infarction; VAD, ventricular assist device; VF, ventricular fibrillation; VT, ventricular tachycardia;OfficerWilliam J. Oetgen, MD, MBA, FACC, Senior Vice Pres-
ident, Science and Quality
Charlene L. May, Senior Director, Science and Clinical
Policy
Melanie Shahriary, RN, BSN, Director, Performance Mea-
Element Definition
out resulting limitations of physical activity. Ordinary physical activity does not
dyspnea.
g in a slight limitation of physical activity. They are comfortable at rest.
atigue, palpitation, or dyspnea.
ng in marked limitation of physical activity. They are comfortable at rest. Less
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ntact. This category includes all deaths regardless of cause of death.
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bleeding nor a stroke
not attributable to either cardiovascular or noncardiovascular cause
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are captopril, enalapril, lisinopril, and ramipril.
are atenolol, metoprolol, propranolol, timolol, esmolol, and labetalol. Some
include atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol,
carvedilol.
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